



Duram 195 (Vertical and Self-Leveling)

Duram Pty Ltd

Chemwatch Hazard Alert Code: 2

Chemwatch: 5236-22

Version No: 7.1

Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Issue Date: 10/03/2023

Print Date: 24/04/2023

L.GHS.AUS.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

| | |
|-------------------------------|---|
| Product name | Duram 195 (Vertical and Self-Leveling) |
| Chemical Name | Not Applicable |
| Synonyms | 195. Liquid polyurethane waterproofing membrane |
| Chemical formula | Not Applicable |
| Other means of identification | Not Available |

Relevant identified uses of the substance or mixture and uses advised against

| | |
|--------------------------|---|
| Relevant identified uses | Designed to waterproof most applications within the building and construction industry. |
|--------------------------|---|

Details of the manufacturer or supplier of the safety data sheet

| | |
|-------------------------|--|
| Registered company name | Duram Pty Ltd |
| Address | 51 Prince William Drive Seven Hills NSW 2147 Australia |
| Telephone | +61 2 9624 4007 |
| Fax | +61 2 9624 4079 |
| Website | www.duram.com.au |
| Email | mail@duram.com.au |

Emergency telephone number

| | |
|-----------------------------------|----------------------------------|
| Association / Organisation | CHEMTREC Australia (Sydney) |
| Emergency telephone numbers | +612 9037 2994 24 hours / 7 days |
| Other emergency telephone numbers | Not Available |

SECTION 2 Hazards identification

Classification of the substance or mixture

HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

COMBUSTIBLE LIQUID, regulated for storage purposes only

Chemwatch Hazard Ratings


| | Min | Max |
|--------------|-----|-----|
| Flammability | 1 | 1 |
| Toxicity | 1 | 1 |
| Body Contact | 2 | 2 |
| Reactivity | 1 | 1 |
| Chronic | 2 | 2 |

0 = Minimum
1 = Low
2 = Moderate
3 = High
4 = Extreme

| | |
|--------------------|--|
| Poisons Schedule | Not Applicable |
| Classification [1] | Flammable Liquids Category 4, Skin Corrosion/Irritation Category 2, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2A, Sensitisation (Respiratory) Category 1, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Carcinogenicity Category 2, Reproductive Toxicity Category 2, Hazardous to the Aquatic Environment Long-Term Hazard Category 3 |
| Legend: | 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI |

Label elements

Duram 195 (Vertical and Self-Leveling)

| | |
|----------------------------|---|
| Hazard pictogram(s) |  |
|----------------------------|---|

| | |
|--------------------|---------------|
| Signal word | Danger |
|--------------------|---------------|

Hazard statement(s)

| | |
|---------------|--|
| H227 | Combustible liquid. |
| H315 | Causes skin irritation. |
| H317 | May cause an allergic skin reaction. |
| H319 | Causes serious eye irritation. |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| H335 | May cause respiratory irritation. |
| H351 | Suspected of causing cancer. |
| H361fd | Suspected of damaging fertility. Suspected of damaging the unborn child. |
| H412 | Harmful to aquatic life with long lasting effects. |

Precautionary statement(s) Prevention

| | |
|-------------|--|
| P201 | Obtain special instructions before use. |
| P210 | Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. |
| P261 | Avoid breathing mist/vapours/spray. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P280 | Wear protective gloves, protective clothing, eye protection and face protection. |
| P284 | [In case of inadequate ventilation] wear respiratory protection. |
| P273 | Avoid release to the environment. |
| P264 | Wash all exposed external body areas thoroughly after handling. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |

Precautionary statement(s) Response

| | |
|-----------------------|--|
| P304+P340 | IF INHALED: Remove person to fresh air and keep comfortable for breathing. |
| P308+P313 | IF exposed or concerned: Get medical advice/ attention. |
| P342+P311 | If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider. |
| P370+P378 | In case of fire: Use alcohol resistant foam or normal protein foam to extinguish. |
| P302+P352 | IF ON SKIN: Wash with plenty of water and soap. |
| P305+P351+P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P312 | Call a POISON CENTER/doctor/physician/first aider/if you feel unwell. |
| P333+P313 | If skin irritation or rash occurs: Get medical advice/attention. |
| P337+P313 | If eye irritation persists: Get medical advice/attention. |
| P362+P364 | Take off contaminated clothing and wash it before reuse. |

Precautionary statement(s) Storage

| | |
|------------------|--|
| P405 | Store locked up. |
| P403+P233 | Store in a well-ventilated place. Keep container tightly closed. |

Precautionary statement(s) Disposal

| | |
|-------------|--|
| P501 | Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation. |
|-------------|--|

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

| CAS No | %[weight] | Name |
|------------|-----------|---|
| 471-34-1 | 30-60 | calcium carbonate |
| 68515-48-0 | 10-30 | diisononyl phthalate |
| 101-68-8 | <10 | 4,4'-diphenylmethane diisocyanate (MDI) |
| 64742-94-5 | <10 | solvent naphtha petroleum, heavy aromatic |
| 64742-95-6 | <10 | naphtha petroleum, light aromatic solvent |
| 95-63-6 | <5 | 1,2,4-trimethyl benzene |
| 1305-78-8 | <5 | calcium oxide |

Duram 195 (Vertical and Self-Leveling)

| CAS No | %[weight] | Name |
|---|-----------|--|
| 5873-54-1 | <1 | <u>2,4'-diphenylmethane diisocyanate</u> |
| 91-20-3 | <0.2 | <u>naphthalene</u> |
| 64741-65-7. | <0.2 | <u>naphtha petroleum, heavy alkylate</u> |
| 4083-64-1 | <0.2 | <u>p-toluenesulfonyl isocyanate</u> |
| 108-67-8 | <0.2 | <u>1,3,5-trimethyl benzene</u> |
| Not Available | balance | Ingredients determined not to be hazardous |
| Legend: 1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available | | |

SECTION 4 First aid measures

Description of first aid measures

| | |
|---------------------|---|
| Eye Contact | <p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> ▶ Wash out immediately with fresh running water. ▶ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▶ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel. |
| Skin Contact | <p>If skin contact occurs:</p> <ul style="list-style-type: none"> ▶ Immediately remove all contaminated clothing, including footwear. ▶ Flush skin and hair with running water (and soap if available). ▶ Seek medical attention in event of irritation. |
| Inhalation | <ul style="list-style-type: none"> ▶ If fumes or combustion products are inhaled remove from contaminated area. ▶ Lay patient down. Keep warm and rested. ▶ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▶ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▶ Transport to hospital, or doctor, without delay. <p>Following uptake by inhalation, move person to an area free from risk of further exposure. Oxygen or artificial respiration should be administered as needed. Asthmatic-type symptoms may develop and may be immediate or delayed up to several hours. Treatment is essentially symptomatic. A physician should be consulted.</p> |
| Ingestion | <ul style="list-style-type: none"> ▶ If swallowed do NOT induce vomiting. ▶ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. ▶ Observe the patient carefully. ▶ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. ▶ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. ▶ Seek medical advice. |

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

for naphthalene intoxication: Naphthalene requires hepatic and microsomal activation prior to the production of toxic effects. Liver microsomes catalyse the initial synthesis of the reactive 1,2-epoxide intermediate which is subsequently oxidised to naphthalene dihydrodiol and alpha-naphthol. The 2-naphthoquinones are thought to produce haemolysis, the 1,2-naphthoquinones are thought to be responsible for producing cataracts in rabbits, and the glutathione-adducts of naphthalene-1,2-oxide are probably responsible for pulmonary toxicity. Suggested treatment regime:

- ▶ Induce emesis and/or perform gastric lavage with large amounts of warm water where oral poisoning is suspected.
- ▶ Instill a saline cathartic such as magnesium or sodium sulfate in water (15 to 30g).
- ▶ Demulcents such as milk, egg white, gelatin, or other protein solutions may be useful after the stomach is emptied but oils should be avoided because they promote absorption.
- ▶ If eyes/skin contaminated, flush with warm water followed by the application of a bland ointment.
- ▶ Severe anaemia, due to haemolysis, may require small repeated blood transfusions, preferably with red cells from a non-sensitive individual.
- ▶ Where intravascular haemolysis, with haemoglobinuria occurs, protect the kidneys by promoting a brisk flow of dilute urine with, for example, an osmotic diuretic such as mannitol. It may be useful to alkalinise the urine with small amounts of sodium bicarbonate but many researchers doubt whether this prevents blockage of the renal tubules.
- ▶ Use supportive measures in the case of acute renal failure. GOSELIN, SMITH HODGE: Clinical Toxicology of Commercial Products, 5th Ed.

For sub-chronic and chronic exposures to isocyanates:

- ▶ This material may be a potent pulmonary sensitiser which causes bronchospasm even in patients without prior airway hyperreactivity.
- ▶ Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts.
- ▶ Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure.
- ▶ Pulmonary symptoms include cough, burning, substernal pain and dyspnoea.
- ▶ Some cross-sensitivity occurs between different isocyanates.
- ▶ Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line.
- ▶ Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids.
- ▶ Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion.
- ▶ Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions.
- ▶ There is no effective therapy for sensitised workers.

[Ellenhorn and Barceloux; Molecular Toxicology]

NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity.

[Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992]

Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who develops chronic respiratory distress when working with isocyanates should be removed from exposure and examined by a physician. Further exposure must be avoided if a sensitivity to isocyanates or polyisocyanates has developed.

SECTION 5 Firefighting measures

Extinguishing media

- ▶ Foam.

Continued...

Duram 195 (Vertical and Self-Leveling)

- ▶ Dry chemical powder.
- ▶ BCF (where regulations permit).
- ▶ Carbon dioxide.
- ▶ Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

| | |
|-----------------------------|--|
| Fire Incompatibility | ▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result |
|-----------------------------|--|

Advice for firefighters

| | |
|------------------------------|---|
| Fire Fighting | <ul style="list-style-type: none"> ▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ Wear full body protective clothing with breathing apparatus. ▶ Prevent, by any means available, spillage from entering drains or water course. ▶ Use water delivered as a fine spray to control fire and cool adjacent area. ▶ Avoid spraying water onto liquid pools. ▶ DO NOT approach containers suspected to be hot. ▶ Cool fire exposed containers with water spray from a protected location. ▶ If safe to do so, remove containers from path of fire. |
| Fire/Explosion Hazard | <ul style="list-style-type: none"> ▶ Combustible. ▶ Slight fire hazard when exposed to heat or flame. ▶ Heating may cause expansion or decomposition leading to violent rupture of containers. ▶ On combustion, may emit toxic fumes of carbon monoxide (CO). ▶ May emit acrid smoke. ▶ Mists containing combustible materials may be explosive. <p>Combustion products include: carbon dioxide (CO₂) isocyanates and minor amounts of hydrogen cyanide nitrogen oxides (NO_x) other pyrolysis products typical of burning organic material. May emit poisonous fumes. May emit corrosive fumes.</p> |
| HAZCHEM | Not Applicable |

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

| | |
|---------------------|--|
| Minor Spills | <p>Environmental hazard - contain spillage.</p> <ul style="list-style-type: none"> ▶ Remove all ignition sources. ▶ Clean up all spills immediately. ▶ Avoid breathing vapours and contact with skin and eyes. ▶ Control personal contact with the substance, by using protective equipment. ▶ Contain and absorb spill with sand, earth, inert material or vermiculite. ▶ Wipe up. ▶ Place in a suitable, labelled container for waste disposal. |
| Major Spills | <p>Environmental hazard - contain spillage.</p> <p>For isocyanate spills of less than 40 litres (2 m²):</p> <ul style="list-style-type: none"> ▶ Evacuate area from everybody not dealing with the emergency, keep them upwind and prevent further access, remove ignition sources and, if inside building, ventilate area as well as possible. ▶ Notify supervision and others as necessary. ▶ Put on personal protective equipment (suitable respiratory protection, face and eye protection, protective suit, gloves and impermeable boots). ▶ Control source of leakage (where applicable). ▶ Dike the spill to prevent spreading and to contain additions of decontaminating solution. ▶ Prevent the material from entering drains. ▶ Estimate spill pool volume or area. ▶ Absorb and decontaminate. - Completely cover the spill with wet sand, wet earth, vermiculite or other similar absorbent. - Add neutraliser (for suitable formulations: see below) to the adsorbent materials (equal to that of estimated spill pool volume). Intensify contact between spill, absorbent and neutraliser by carefully mixing with a rake and allow to react for 15 minutes ▶ Shovel absorbent/decontaminant solution mixture into a steel drum. ▶ Decontaminate surface. - Pour an equal amount of neutraliser solution over contaminated surface. - Scrub area with a stiff bristle brush, using moderate pressure. - Completely cover decontaminant with vermiculite or other similar absorbent. - After 5 minutes, shovel absorbent/decontamination solution mixture into the same steel drum used above. ▶ Monitor for residual isocyanate. If surface is decontaminated, proceed to next step. If contamination persists, repeat decontaminate procedure immediately above ▶ Place loosely covered drum (release of carbon dioxide) outside for at least 72 hours. Label waste-containing drum appropriately. Remove waste materials for incineration. ▶ Decontaminate and remove personal protective equipment. ▶ Return to normal operation. ▶ Conduct accident investigation and consider measures to prevent reoccurrence. <p>Decontamination: Treat isocyanate spills with sufficient amounts of isocyanate decontaminant preparation ("neutralising fluid"). Isocyanates and polyisocyanates are generally not miscible with water. Liquid surfactants are necessary to allow better dispersion of isocyanate and neutralising fluids/preparations. Alkaline neutralisers react faster than water/surfactant mixtures alone. Typically, such a preparation may consist of:</p> |

Continued...

Duram 195 (Vertical and Self-Leveling)

Sawdust: 20 parts by weight Kieselguhr 40 parts by weight plus a mixture of (ammonia (s.g. 0.880) 8% v/v non-ionic surfactant 2% v/v water 90% v/v).

Let stand for 24 hours

Three commonly used neutralising fluids each exhibit advantages in different situations.

Formulation A :

liquid surfactant 0.2-2%

sodium carbonate 5-10%

water to 100%

Formulation B

liquid surfactant 0.2-2%

concentrated ammonia 3-8%

water to 100%

Formulation C

ethanol, isopropanol or butanol 50%

concentrated ammonia 5%

water to 100%

After application of any of these formulae, let stand for 24 hours.

Formulation B reacts faster than Formulation A. However, ammonia-based neutralisers should be used only under well-ventilated conditions to avoid overexposure to ammonia or if members of the emergency team wear suitable respiratory protection. Formulation C is especially suitable for cleaning of equipment from unreacted isocyanate and neutralizing under freezing conditions. Regard has to be taken to the flammability of the alcoholic solution.

- ▶ Avoid contamination with water, alkalis and detergent solutions.
- ▶ Material reacts with water and generates gas, pressurises containers with even drum rupture resulting.
- ▶ **DO NOT reseal container if contamination is suspected.**
- ▶ Open all containers with care.

Moderate hazard.

- ▶ Clear area of personnel and move upwind.
- ▶ Alert Fire Brigade and tell them location and nature of hazard.
- ▶ Wear breathing apparatus plus protective gloves.
- ▶ Prevent, by any means available, spillage from entering drains or water course.
- ▶ No smoking, naked lights or ignition sources.
- ▶ Increase ventilation.
- ▶ Stop leak if safe to do so.
- ▶ Contain spill with sand, earth or vermiculite.
- ▶ Collect recoverable product into labelled containers for recycling.
- ▶ Absorb remaining product with sand, earth or vermiculite.
- ▶ Collect solid residues and seal in labelled drums for disposal.
- ▶ Wash area and prevent runoff into drains.
- ▶ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling

- ▶ **DO NOT allow clothing wet with material to stay in contact with skin**
- ▶ Avoid all personal contact, including inhalation.
- ▶ Wear protective clothing when risk of exposure occurs.
- ▶ Use in a well-ventilated area.
- ▶ Prevent concentration in hollows and sumps.
- ▶ **DO NOT enter confined spaces until atmosphere has been checked.**
- ▶ Avoid smoking, naked lights or ignition sources.
- ▶ Avoid contact with incompatible materials.
- ▶ When handling, **DO NOT eat, drink or smoke.**
- ▶ Keep containers securely sealed when not in use.
- ▶ Avoid physical damage to containers.
- ▶ Always wash hands with soap and water after handling.
- ▶ Work clothes should be laundered separately.
- ▶ Use good occupational work practice.
- ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.
- ▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.

Other information

- for commercial quantities of isocyanates:
- Isocyanates should be stored in adequately banded areas. Nothing else should be kept within the same banding. Pre-polymers need not be segregated. Drums of isocyanates should be stored under cover, out of direct sunlight, protected from rain, protected from physical damage and well away from moisture, acids and alkalis.
- Where isocyanates are stored at elevated temperatures to prevent solidifying, adequate controls should be installed to prevent the high temperatures and precautions against fire should be taken.
- Where stored in tanks, the more reactive isocyanates should be blanketed with a non-reactive gas such as nitrogen and equipped with absorptive type breather valve (to prevent vapour emissions)..
- Transfer systems for isocyanates in bulk storage should be fully enclosed and use pump or vacuum systems. Warning signs, in appropriate languages, should be posted where necessary.
- Areas in which polyurethane foam products are stored should be supplied with good general ventilation. Residual amounts of unreacted isocyanate may be present in the finished foam, resulting in hazardous atmospheric concentrations.
- Ideal storage temperature range is dependent on the specific polymer due to viscosity and melting point differences between the polymers. Use 25 deg C (77 deg F) to 30 deg C (86 deg F) as a guideline to most liquid isocyanates for optimum storage temperature. If some isocyanates are stored at or below a temperature of 25 deg C (77 deg F), crystallization and settling of the isocyanate may occur. Storage in a cold warehouse can cause crystals to form. These crystals can settle to the bottom of the container. If crystals do form, they can be melted easily with moderate heat. It is suggested that a container the size of a drum be warmed for 16-24 hours at sufficient temperature to melt the crystals. When the crystals are melted, the container should be agitated by rolling or stirring, until the contents are homogenous. Since heated isocyanate will generate vapors more rapidly than product stored at 25 deg C (77 deg F), be sure to follow the precautions under the Personal Protection.
- ▶ Store in original containers.
- ▶ Keep containers securely sealed.
- ▶ No smoking, naked lights or ignition sources.

Duram 195 (Vertical and Self-Leveling)

- ▶ Store in a cool, dry, well-ventilated area.
- ▶ Store away from incompatible materials and foodstuff containers.
- ▶ Protect containers against physical damage and check regularly for leaks.
- ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

| | |
|--------------------------------|---|
| Suitable container | <ul style="list-style-type: none"> ▶ Metal can or drum ▶ Packaging as recommended by manufacturer. ▶ Check all containers are clearly labelled and free from leaks. |
| Storage incompatibility | <ul style="list-style-type: none"> ▶ Avoid reaction with oxidising agents ▶ Avoid strong acids, bases. ▶ Avoid strong acids, acid chlorides, acid anhydrides and chloroformates. ▶ Avoid contamination with water, alkalies and detergent solutions. ▶ Material reacts with water and generates gas, pressurises containers with even drum rupture resulting. ▶ DO NOT reseal container if contamination is suspected. ▶ Open all containers with care. |

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

| Source | Ingredient | Material name | TWA | STEL | Peak | Notes |
|------------------------------|---|--------------------------------------|-------------------------------|-------------------------------|---------------|--|
| Australia Exposure Standards | calcium carbonate | Calcium carbonate | 10 mg/m ³ | Not Available | Not Available | (a) This value is for inhalable dust containing no asbestos and < 1% crystalline silica. |
| Australia Exposure Standards | 4,4'-diphenylmethane diisocyanate (MDI) | Methylene bisphenyl isocyanate (MDI) | 0.02 mg/m ³ | 0.07 mg/m ³ | Not Available | Not Available |
| Australia Exposure Standards | calcium oxide | Calcium oxide | 2 mg/m ³ | Not Available | Not Available | Not Available |
| Australia Exposure Standards | 2,4'-diphenylmethane diisocyanate | Isocyanates, all (as-NCO) | 0.02 mg/m ³ | 0.07 mg/m ³ | Not Available | Not Available |
| Australia Exposure Standards | naphthalene | Naphthalene | 10 ppm / 52 mg/m ³ | 79 mg/m ³ / 15 ppm | Not Available | Not Available |
| Australia Exposure Standards | p-toluenesulfonyl isocyanate | Isocyanates, all (as-NCO) | 0.02 mg/m ³ | 0.07 mg/m ³ | Not Available | Not Available |

Emergency Limits

| Ingredient | TEEL-1 | TEEL-2 | TEEL-3 |
|---|-------------------------|-------------------------|--------------------------|
| calcium carbonate | 45 mg/m ³ | 210 mg/m ³ | 1,300 mg/m ³ |
| 4,4'-diphenylmethane diisocyanate (MDI) | 0.45 mg/m ³ | Not Available | Not Available |
| 4,4'-diphenylmethane diisocyanate (MDI) | 29 mg/m ³ | 40 mg/m ³ | 240 mg/m ³ |
| naphtha petroleum, light aromatic solvent | 1,200 mg/m ³ | 6,700 mg/m ³ | 40,000 mg/m ³ |
| 1,2,4-trimethyl benzene | 140 mg/m ³ | 360 mg/m ³ | 2,200 mg/m ³ |
| 1,2,4-trimethyl benzene | Not Available | Not Available | 480 ppm |
| calcium oxide | 6 mg/m ³ | 110 mg/m ³ | 660 mg/m ³ |
| naphthalene | 15 ppm | 83 ppm | 500 ppm |
| 1,3,5-trimethyl benzene | Not Available | Not Available | 480 ppm |

| Ingredient | Original IDLH | Revised IDLH |
|---|----------------------|---------------|
| calcium carbonate | Not Available | Not Available |
| diisononyl phthalate | Not Available | Not Available |
| 4,4'-diphenylmethane diisocyanate (MDI) | 75 mg/m ³ | Not Available |
| solvent naphtha petroleum, heavy aromatic | Not Available | Not Available |
| naphtha petroleum, light aromatic solvent | Not Available | Not Available |
| 1,2,4-trimethyl benzene | Not Available | Not Available |
| calcium oxide | 25 mg/m ³ | Not Available |
| 2,4'-diphenylmethane diisocyanate | Not Available | Not Available |
| naphthalene | 250 ppm | Not Available |
| naphtha petroleum, heavy alkylate | Not Available | Not Available |
| p-toluenesulfonyl isocyanate | Not Available | Not Available |

Duram 195 (Vertical and Self-Leveling)

| Ingredient | Original IDLH | Revised IDLH |
|-------------------------|---------------|---------------|
| 1,3,5-trimethyl benzene | Not Available | Not Available |

Occupational Exposure Banding

| Ingredient | Occupational Exposure Band Rating | Occupational Exposure Band Limit |
|-------------------------|-----------------------------------|----------------------------------|
| diisononyl phthalate | E | ≤ 0.1 ppm |
| 1,2,4-trimethyl benzene | E | ≤ 0.1 ppm |
| 1,3,5-trimethyl benzene | E | ≤ 0.1 ppm |

Notes: Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

MATERIAL DATA

NOTE P: The classification as a carcinogen need not apply if it can be shown that the substance contains less than 0.01% w/w benzene (EINECS No 200-753-7). Note E shall also apply when the substance is classified as a carcinogen. This note applies only to certain complex oil-derived substances in Annex VI.

European Union (EU) List of harmonised classification and labelling hazardous substances, Table 3.1, Annex VI, Regulation (EC) No 1272/2008 (CLP) - up to the latest ATP

Exposure controls

| Appropriate engineering controls | <p>Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.</p> <p>The basic types of engineering controls are:</p> <p>Process controls which involve changing the way a job activity or process is done to reduce the risk.</p> <p>Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.</p> <p>Employers may need to use multiple types of controls to prevent employee overexposure.</p> <p>Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection. An approved self contained breathing apparatus (SCBA) may be required in some situations.</p> <p>Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.</p> <table border="1"> <thead> <tr> <th>Type of Contaminant:</th> <th>Air Speed:</th> </tr> </thead> <tbody> <tr> <td>solvent, vapours, degreasing etc., evaporating from tank (in still air).</td> <td>0.25-0.5 m/s (50-100 f/min.)</td> </tr> <tr> <td>aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)</td> <td>0.5-1 m/s (100-200 f/min.)</td> </tr> <tr> <td>direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)</td> <td>1-2.5 m/s (200-500 f/min.)</td> </tr> <tr> <td>grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).</td> <td>2.5-10 m/s (500-2000 f/min.)</td> </tr> </tbody> </table> <p>Within each range the appropriate value depends on:</p> <table border="1"> <thead> <tr> <th>Lower end of the range</th> <th>Upper end of the range</th> </tr> </thead> <tbody> <tr> <td>1: Room air currents minimal or favourable to capture</td> <td>1: Disturbing room air currents</td> </tr> <tr> <td>2: Contaminants of low toxicity or of nuisance value only.</td> <td>2: Contaminants of high toxicity</td> </tr> <tr> <td>3: Intermittent, low production.</td> <td>3: High production, heavy use</td> </tr> <tr> <td>4: Large hood or large air mass in motion</td> <td>4: Small hood-local control only</td> </tr> </tbody> </table> <p>Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.</p> | Type of Contaminant: | Air Speed: | solvent, vapours, degreasing etc., evaporating from tank (in still air). | 0.25-0.5 m/s (50-100 f/min.) | aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation) | 0.5-1 m/s (100-200 f/min.) | direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion) | 1-2.5 m/s (200-500 f/min.) | grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion). | 2.5-10 m/s (500-2000 f/min.) | Lower end of the range | Upper end of the range | 1: Room air currents minimal or favourable to capture | 1: Disturbing room air currents | 2: Contaminants of low toxicity or of nuisance value only. | 2: Contaminants of high toxicity | 3: Intermittent, low production. | 3: High production, heavy use | 4: Large hood or large air mass in motion | 4: Small hood-local control only |
|---|---|----------------------|------------|--|---------------------------------|---|----------------------------|--|----------------------------|--|---------------------------------|------------------------|------------------------|---|---------------------------------|--|----------------------------------|----------------------------------|-------------------------------|---|----------------------------------|
| | Type of Contaminant: | Air Speed: | | | | | | | | | | | | | | | | | | | |
| solvent, vapours, degreasing etc., evaporating from tank (in still air). | 0.25-0.5 m/s (50-100 f/min.) | | | | | | | | | | | | | | | | | | | | |
| aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation) | 0.5-1 m/s (100-200 f/min.) | | | | | | | | | | | | | | | | | | | | |
| direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion) | 1-2.5 m/s (200-500 f/min.) | | | | | | | | | | | | | | | | | | | | |
| grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion). | 2.5-10 m/s (500-2000 f/min.) | | | | | | | | | | | | | | | | | | | | |
| Lower end of the range | Upper end of the range | | | | | | | | | | | | | | | | | | | | |
| 1: Room air currents minimal or favourable to capture | 1: Disturbing room air currents | | | | | | | | | | | | | | | | | | | | |
| 2: Contaminants of low toxicity or of nuisance value only. | 2: Contaminants of high toxicity | | | | | | | | | | | | | | | | | | | | |
| 3: Intermittent, low production. | 3: High production, heavy use | | | | | | | | | | | | | | | | | | | | |
| 4: Large hood or large air mass in motion | 4: Small hood-local control only | | | | | | | | | | | | | | | | | | | | |
| Individual protection measures, such as personal protective equipment |  | | | | | | | | | | | | | | | | | | | | |
| Eye and face protection | <ul style="list-style-type: none"> ▶ Safety glasses with side shields. ▶ Chemical goggles. ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent] | | | | | | | | | | | | | | | | | | | | |
| Skin protection | See Hand protection below | | | | | | | | | | | | | | | | | | | | |
| Hands/feet protection | <ul style="list-style-type: none"> ▶ Wear chemical protective gloves, e.g. PVC. ▶ Wear safety footwear or safety gumboots, e.g. Rubber <p>NOTE:</p> <ul style="list-style-type: none"> ▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. ▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed. <p>The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to</p> | | | | | | | | | | | | | | | | | | | | |

Duram 195 (Vertical and Self-Leveling)

manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

The exact breakthrough time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.

Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:

- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and
- dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).

· When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

· When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.

· Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.

· Contaminated gloves should be replaced.

As defined in ASTM F-739-96 in any application, gloves are rated as:

- Excellent when breakthrough time > 480 min
- Good when breakthrough time > 20 min
- Fair when breakthrough time < 20 min
- Poor when glove material degrades

For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.

It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.

Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task.

Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:

· Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.

· Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Body protection See Other protection below

Other protection

- ▶ Overalls.
- ▶ P.V.C apron.
- ▶ Barrier cream.
- ▶ Skin cleansing cream.
- ▶ Eye wash unit.

Recommended material(s)**GLOVE SELECTION INDEX**

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the **computer-generated** selection:

Duram 195 (Vertical and Self-Leveling)

| Material | CPI |
|------------|-----|
| PE/EVAL/PE | C |
| TEFLON | C |

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

- ▶ Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- ▶ The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- ▶ Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used
- ▶ In certain circumstances, personal protection of the individual employee is necessary. Personal protective devices should be regarded as being supplementary to substitution and engineering control and should not be used in preference to them as they do nothing to eliminate the hazard.
- ▶ However, in some situations, minimising exposure to isocyanates by enclosure and ventilation is not possible, and occupational exposure standards may be exceeded, particularly during on-site mixing of paints, spray-painting, foaming and maintenance of machine and ventilation systems. In these situations, air-line respirators or self-contained breathing apparatus complying with the appropriate national standard must be used.
- ▶ **Organic vapour respirators with particulate pre- filters and powered, air-purifying respirators are NOT suitable.**
- ▶ Personal protective equipment must be appropriately selected, individually fitted and workers trained in their correct use and maintenance. Personal protective equipment must be regularly checked and maintained to ensure that the worker is being protected.
- ▶ Air- line respirators or self-contained breathing apparatus complying with the appropriate national standard should be used during the clean-up of spills and the repair or clean-up of contaminated equipment and similar situations which cause emergency exposures to hazardous atmospheric concentrations of isocyanate.

SECTION 9 Physical and chemical properties**Information on basic physical and chemical properties**

| | | | |
|-----------------------|--|-------------------------------------|------|
| Appearance | Dark brown to black liquid with a characteristic odour; does not mix with water. | | |
| Physical state | Liquid | Relative density (Water = 1) | 1.39 |

Continued...

Duram 195 (Vertical and Self-Leveling)

| | | | |
|---|----------------|--|----------------|
| Odour | Not Available | Partition coefficient n-octanol / water | Not Available |
| Odour threshold | Not Available | Auto-ignition temperature (°C) | Not Available |
| pH (as supplied) | Not Applicable | Decomposition temperature (°C) | Not Available |
| Melting point / freezing point (°C) | Not Available | Viscosity (cSt) | Not Available |
| Initial boiling point and boiling range (°C) | 160 | Molecular weight (g/mol) | Not Applicable |
| Flash point (°C) | 75 | Taste | Not Available |
| Evaporation rate | Not Available | Explosive properties | Not Available |
| Flammability | Combustible. | Oxidising properties | Not Available |
| Upper Explosive Limit (%) | Not Available | Surface Tension (dyn/cm or mN/m) | Not Available |
| Lower Explosive Limit (%) | Not Available | Volatile Component (%vol) | Not Available |
| Vapour pressure (kPa) | Not Available | Gas group | Not Available |
| Solubility in water | Immiscible | pH as a solution (1%) | Not Applicable |
| Vapour density (Air = 1) | Not Available | VOC g/L | Not Available |

SECTION 10 Stability and reactivity

| | |
|---|--|
| Reactivity | See section 7 |
| Chemical stability | <ul style="list-style-type: none"> ▶ Unstable in the presence of incompatible materials. ▶ Product is considered stable. ▶ Hazardous polymerisation will not occur. |
| Possibility of hazardous reactions | See section 7 |
| Conditions to avoid | See section 7 |
| Incompatible materials | See section 7 |
| Hazardous decomposition products | See section 5 |

SECTION 11 Toxicological information

Information on toxicological effects

| | |
|---------------------|--|
| Inhaled | <p>Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.</p> <p>Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may be damaging to the health of the individual.</p> |
| Ingestion | Accidental ingestion of the material may be damaging to the health of the individual. |
| Skin Contact | <p>The material produces moderate skin irritation; evidence exists, or practical experience predicts, that the material either</p> <ul style="list-style-type: none"> ▶ produces moderate inflammation of the skin in a substantial number of individuals following direct contact, and/or ▶ produces significant, but moderate, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. <p>Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p> <p>Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.</p> <p>Open cuts, abraded or irritated skin should not be exposed to this material</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p> |
| Eye | <p>Evidence exists, or practical experience predicts, that the material may cause severe eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Eye contact may cause significant inflammation with pain. Corneal injury may occur; permanent impairment of vision may result unless treatment is prompt and adequate. Repeated or prolonged exposure to irritants may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p> |
| Chronic | <p>On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.</p> <p>Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems.</p> <p>Practical evidence shows that inhalation of the material is capable of inducing a sensitisation reaction in a substantial number of individuals at a greater frequency than would be expected from the response of a normal population.</p> <p>Pulmonary sensitisation, resulting in hyperactive airway dysfunction and pulmonary allergy may be accompanied by fatigue, malaise and aching.</p> <p>Significant symptoms of exposure may persist for extended periods, even after exposure ceases. Symptoms can be activated by a variety of nonspecific environmental stimuli such as automobile exhaust, perfumes and passive smoking.</p> <p>Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.</p> <p>Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to</p> |

Duram 195 (Vertical and Self-Leveling)

| | <p>become hyper-responsive.</p> <p>Substances that can cause occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers. Wherever it is reasonably practicable, exposure to substances that can cause occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.</p> <p>Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.</p> <p>Exposure to the material may cause concerns for human fertility, generally on the basis that results in animal studies provide sufficient evidence to cause a strong suspicion of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects, but which are not a secondary non-specific consequence of other toxic effects.</p> <p>Exposure to the material may cause concerns for humans owing to possible developmental toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects.</p> <p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p> | | | | | | | | | | |
|--|--|----------|------------|--|---|--|--|--|---|--|--|
| Duram 195 (Vertical and Self-Leveling) | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Not Available</td> <td>Not Available</td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Not Available | Not Available | | | | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Not Available | Not Available | | | | | | | | | | |
| calcium carbonate | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>dermal (rat) LD50: >2000 mg/kg^[1]</td> <td>Eye (rabbit): 0.75 mg/24h - SEVERE</td> </tr> <tr> <td>Inhalation(Rat) LC50: >3 mg/l4h^[1]</td> <td>Eye: no adverse effect observed (not irritating)^[1]</td> </tr> <tr> <td>Oral (Rat) LD50: >2000 mg/kg^[1]</td> <td>Skin (rabbit): 500 mg/24h-moderate</td> </tr> <tr> <td></td> <td>Skin: no adverse effect observed (not irritating)^[1]</td> </tr> </tbody> </table> | TOXICITY | IRRITATION | dermal (rat) LD50: >2000 mg/kg ^[1] | Eye (rabbit): 0.75 mg/24h - SEVERE | Inhalation(Rat) LC50: >3 mg/l4h ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | Oral (Rat) LD50: >2000 mg/kg ^[1] | Skin (rabbit): 500 mg/24h-moderate | | Skin: no adverse effect observed (not irritating) ^[1] |
| TOXICITY | IRRITATION | | | | | | | | | | |
| dermal (rat) LD50: >2000 mg/kg ^[1] | Eye (rabbit): 0.75 mg/24h - SEVERE | | | | | | | | | | |
| Inhalation(Rat) LC50: >3 mg/l4h ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | | | | | | | | | | |
| Oral (Rat) LD50: >2000 mg/kg ^[1] | Skin (rabbit): 500 mg/24h-moderate | | | | | | | | | | |
| | Skin: no adverse effect observed (not irritating) ^[1] | | | | | | | | | | |
| diisononyl phthalate | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Dermal (rabbit) LD50: >3160 mg/kg^[2]</td> <td>Not Available</td> </tr> <tr> <td>Inhalation(Rat) LC50: >4.4 mg/l4h^[1]</td> <td></td> </tr> <tr> <td>Oral (Rat) LD50: >10000 mg/kg^[2]</td> <td></td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Dermal (rabbit) LD50: >3160 mg/kg ^[2] | Not Available | Inhalation(Rat) LC50: >4.4 mg/l4h ^[1] | | Oral (Rat) LD50: >10000 mg/kg ^[2] | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Dermal (rabbit) LD50: >3160 mg/kg ^[2] | Not Available | | | | | | | | | | |
| Inhalation(Rat) LC50: >4.4 mg/l4h ^[1] | | | | | | | | | | | |
| Oral (Rat) LD50: >10000 mg/kg ^[2] | | | | | | | | | | | |
| 4,4'-diphenylmethane diisocyanate (MDI) | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Dermal (rabbit) LD50: >6200 mg/kg^[2]</td> <td>Eye: no adverse effect observed (not irritating)^[1]</td> </tr> <tr> <td>Inhalation(Rat) LC50: 0.368 mg/L4h^[1]</td> <td>Skin (rabbit): 500 mg /24 hours Dermal Sensitiser *Respiratory Sensitiser (g.pig) [* = Bayer CCINFO 2133615]</td> </tr> <tr> <td>Oral (Mouse) LD50: 2200 mg/kg^[2]</td> <td>Skin: adverse effect observed (irritating)^[1]</td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Dermal (rabbit) LD50: >6200 mg/kg ^[2] | Eye: no adverse effect observed (not irritating) ^[1] | Inhalation(Rat) LC50: 0.368 mg/L4h ^[1] | Skin (rabbit): 500 mg /24 hours Dermal Sensitiser *Respiratory Sensitiser (g.pig) [* = Bayer CCINFO 2133615] | Oral (Mouse) LD50: 2200 mg/kg ^[2] | Skin: adverse effect observed (irritating) ^[1] | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Dermal (rabbit) LD50: >6200 mg/kg ^[2] | Eye: no adverse effect observed (not irritating) ^[1] | | | | | | | | | | |
| Inhalation(Rat) LC50: 0.368 mg/L4h ^[1] | Skin (rabbit): 500 mg /24 hours Dermal Sensitiser *Respiratory Sensitiser (g.pig) [* = Bayer CCINFO 2133615] | | | | | | | | | | |
| Oral (Mouse) LD50: 2200 mg/kg ^[2] | Skin: adverse effect observed (irritating) ^[1] | | | | | | | | | | |
| solvent naphtha petroleum, heavy aromatic | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Dermal (rabbit) LD50: >2000 mg/kg^[2]</td> <td>Eye (rabbit): Irritating [PETROFIN]</td> </tr> <tr> <td>Inhalation(Rat) LC50: >0.003 mg/L4h^[1]</td> <td>Eye: no adverse effect observed (not irritating)^[1]</td> </tr> <tr> <td>Oral (Rat) LD50: >2000 mg/kg^[1]</td> <td>Skin: adverse effect observed (irritating)^[1]</td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Dermal (rabbit) LD50: >2000 mg/kg ^[2] | Eye (rabbit): Irritating [PETROFIN] | Inhalation(Rat) LC50: >0.003 mg/L4h ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | Oral (Rat) LD50: >2000 mg/kg ^[1] | Skin: adverse effect observed (irritating) ^[1] | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Dermal (rabbit) LD50: >2000 mg/kg ^[2] | Eye (rabbit): Irritating [PETROFIN] | | | | | | | | | | |
| Inhalation(Rat) LC50: >0.003 mg/L4h ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | | | | | | | | | | |
| Oral (Rat) LD50: >2000 mg/kg ^[1] | Skin: adverse effect observed (irritating) ^[1] | | | | | | | | | | |
| naphtha petroleum, light aromatic solvent | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Dermal (rabbit) LD50: >1900 mg/kg^[1]</td> <td>Eye: no adverse effect observed (not irritating)^[1]</td> </tr> <tr> <td>Inhalation(Rat) LC50: >4.42 mg/L4h^[1]</td> <td>Skin: adverse effect observed (irritating)^[1]</td> </tr> <tr> <td>Oral (Rat) LD50: >4500 mg/kg^[1]</td> <td></td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Dermal (rabbit) LD50: >1900 mg/kg ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | Inhalation(Rat) LC50: >4.42 mg/L4h ^[1] | Skin: adverse effect observed (irritating) ^[1] | Oral (Rat) LD50: >4500 mg/kg ^[1] | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Dermal (rabbit) LD50: >1900 mg/kg ^[1] | Eye: no adverse effect observed (not irritating) ^[1] | | | | | | | | | | |
| Inhalation(Rat) LC50: >4.42 mg/L4h ^[1] | Skin: adverse effect observed (irritating) ^[1] | | | | | | | | | | |
| Oral (Rat) LD50: >4500 mg/kg ^[1] | | | | | | | | | | | |
| 1,2,4-trimethyl benzene | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Dermal (rabbit) LD50: >3160 mg/kg^[2]</td> <td>Not Available</td> </tr> <tr> <td>Inhalation(Rat) LC50: 18 mg/L4h^[2]</td> <td></td> </tr> <tr> <td>Oral (Rat) LD50: 6000 mg/kg^[1]</td> <td></td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Dermal (rabbit) LD50: >3160 mg/kg ^[2] | Not Available | Inhalation(Rat) LC50: 18 mg/L4h ^[2] | | Oral (Rat) LD50: 6000 mg/kg ^[1] | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Dermal (rabbit) LD50: >3160 mg/kg ^[2] | Not Available | | | | | | | | | | |
| Inhalation(Rat) LC50: 18 mg/L4h ^[2] | | | | | | | | | | | |
| Oral (Rat) LD50: 6000 mg/kg ^[1] | | | | | | | | | | | |
| calcium oxide | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>dermal (rat) LD50: >2000 mg/kg^[1]</td> <td>Eye: adverse effect observed (irreversible damage)^[1]</td> </tr> <tr> <td>Inhalation(Rat) LC50: >3 mg/l4h^[1]</td> <td>Skin: adverse effect observed (irritating)^[1]</td> </tr> <tr> <td>Oral (Rat) LD50: >2000 mg/kg^[1]</td> <td></td> </tr> </tbody> </table> | TOXICITY | IRRITATION | dermal (rat) LD50: >2000 mg/kg ^[1] | Eye: adverse effect observed (irreversible damage) ^[1] | Inhalation(Rat) LC50: >3 mg/l4h ^[1] | Skin: adverse effect observed (irritating) ^[1] | Oral (Rat) LD50: >2000 mg/kg ^[1] | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| dermal (rat) LD50: >2000 mg/kg ^[1] | Eye: adverse effect observed (irreversible damage) ^[1] | | | | | | | | | | |
| Inhalation(Rat) LC50: >3 mg/l4h ^[1] | Skin: adverse effect observed (irritating) ^[1] | | | | | | | | | | |
| Oral (Rat) LD50: >2000 mg/kg ^[1] | | | | | | | | | | | |
| 2,4'-diphenylmethane diisocyanate | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>Not Available</td> <td>Not Available</td> </tr> </tbody> </table> | TOXICITY | IRRITATION | Not Available | Not Available | | | | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| Not Available | Not Available | | | | | | | | | | |
| naphthalene | <table border="1"> <thead> <tr> <th>TOXICITY</th> <th>IRRITATION</th> </tr> </thead> <tbody> <tr> <td>dermal (rat) LD50: >2500 mg/kg^[2]</td> <td>Eye (rabbit): 100 mg - mild</td> </tr> <tr> <td>Inhalation(Rat) LC50: >0.4 mg/l4h^[1]</td> <td>Skin (rabbit):495 mg (open) - mild</td> </tr> <tr> <td>Oral (Rat) LD50: 490 mg/kg^[2]</td> <td></td> </tr> </tbody> </table> | TOXICITY | IRRITATION | dermal (rat) LD50: >2500 mg/kg ^[2] | Eye (rabbit): 100 mg - mild | Inhalation(Rat) LC50: >0.4 mg/l4h ^[1] | Skin (rabbit):495 mg (open) - mild | Oral (Rat) LD50: 490 mg/kg ^[2] | | | |
| TOXICITY | IRRITATION | | | | | | | | | | |
| dermal (rat) LD50: >2500 mg/kg ^[2] | Eye (rabbit): 100 mg - mild | | | | | | | | | | |
| Inhalation(Rat) LC50: >0.4 mg/l4h ^[1] | Skin (rabbit):495 mg (open) - mild | | | | | | | | | | |
| Oral (Rat) LD50: 490 mg/kg ^[2] | | | | | | | | | | | |

Duram 195 (Vertical and Self-Leveling)

| | | |
|-----------------------------------|---|---|
| naphtha petroleum, heavy alkylate | TOXICITY | IRRITATION |
| | Dermal (rabbit) LD50: >2000 mg/kg ^[2] | Not Available |
| | Inhalation(Rat) LC50: >5.04 mg/l4h ^[2] | |
| | Oral (Rat) LD50: >7000 mg/kg ^[2] | |
| p-toluenesulfonyl isocyanate | TOXICITY | IRRITATION |
| | dermal (rat) LD50: >2000 mg/kg ^[1] | Not Available |
| | Inhalation(Rat) LC50: >320 ppm4h ^[2] | |
| | Oral (Rat) LD50: 2600 mg/kg ^[2] | |
| 1,3,5-trimethyl benzene | TOXICITY | IRRITATION |
| | dermal (rat) LD50: >3460 mg/kg ^[1] | Eye (rabbit): 500 mg/24h mild |
| | Inhalation(Rat) LC50: 24 mg/L4h ^[2] | Eye: adverse effect observed (irritating) ^[1] |
| | Oral (Rat) LD50: 6000 mg/kg ^[1] | Skin (rabbit): 20 mg/24h moderate |
| | | Skin: adverse effect observed (irritating) ^[1] |
| Legend: | 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances | |

| | |
|-----------------------------|---|
| CALCIUM CARBONATE | No evidence of carcinogenic properties. No evidence of mutagenic or teratogenic effects. The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis. |
| DIISONONYL PHTHALATE | <p>[Huls] The effects of DINP on fertility-related parameters such as reduced testosterone content and production and altered reproductive organ weights (with or without histopathologies) have been demonstrated in rats. Although quantitatively being less potent, DINP has exhibited adverse effects on the male reproductive system and sexual differentiation during development in a number of rodent studies (e.g. increased nipple retention, testicular pathology and decreased AGD/AGI in male offspring), which are components of the antiandrogenic pattern observed with diethylhexyl phthalate (DEHP) (a known reproductive toxicant). Foetal expression of genes involved in androgen synthesis such as StAR and Cyp11a were also reduced. There was also a report of increased gene expression levels of InsI3 (a foetal Leydig cell product critical for testis descent) that may infer the impaired testicular steroidogenesis following exposure to DINP at high doses (e.g. = 750 mg/kg bw/d). Reduced InsI3 was also reported in numerous studies with DEHP. Considering the chemical composition of DINP, which is represented as mixed phthalates with side-chains made up of 5?10% methylethylhexyl, limited evidence of the toxicological properties of transitional phthalates may be expected at high doses of DINP tested The reduced pup weight was observed at approximately 100 mg/kg bw/d in both sexes, both in one- and two-generation reproductive studies in rats, in the absence of overt maternal toxicity. The pup weight reduction was also sustained and not considered solely related to low birth weight. In a post-natal toxicity study, reduced pup weight was also reduced at = 250 mg/kg bw/d. Therefore, this adverse effect of DINP is assessed as the most sensitive endpoint on offspring development. Overall, the available human data do not provide sufficient evidence for a causal relationship between exposure to DINP and adverse health effects in humans. There is also insufficient information to examine the mode of action of DINP on male reproductive tract development and sexual function in comparison with transitional phthalates. However, elements of the plausible mode of action for DINP effects on the male reproductive system, offspring growth and sexual differentiation are considered likely to be parallel in rats and humans if the exposure to DINP is high and within a critical window of development. Therefore, the effects observed in animal studies are regarded as relevant to a human risk assessment.</p> <p>High Molecular Weight Phthalate Esters (HMWPEs) Category as defined by the Phthalate Esters Panel HPV Testing Group (2001) and OECD (2004). The HMWPE group includes chemically similar substances produced from alcohols having backbone carbon lengths of >= 7. Due to their similar chemical structure, category members are generally similar with respect to physicochemical, biological and toxicological properties or display an expected trend. Thus, read-across for toxicity endpoints is an appropriate approach to characterise selected endpoints for members of this category.</p> <p>In some cases the substances have ester side group constituents that span two subcategories (i.e., transitional and high molecular weight constituents). If the level of C4 to C6 constituents in the substance exceeded 10%,the substance was conservatively placed in the transitional subcategory.</p> <p>High molecular weight phthalates are used nearly exclusively as plasticisers of PVC.</p> <p>They are very poorly soluble in water, and have very low vapor pressure. The extant database demonstrates that these substances have few biological effects. A notable exception to this generalisation is that hepatocarcinogenicity has been observed for diisononyl phthalate (DINP). The hepatocarcinogenicity effects of DINP are by a mechanism (peroxisomal proliferation) to which rodents are particularly sensitive. However, it does not appear to be relevant to humans.</p> <p>The high molecular weight phthalates all demonstrate minimal acute toxicity, are not genotoxic, exhibit some liver and kidney effects at high doses, and are negative for reproductive and developmental effects. Further, the available data indicate that the toxicological activity of these molecules diminishes with increasing molecular weight.</p> <p>Studies on HMWPEs indicate that they are rapidly metabolised in the gastrointestinal tract to the corresponding monoester, absorbed and excreted primarily in the urine.</p> <p>Acute toxicity: The available data on phthalates spanning the carbon range from C8-C13 indicate that phthalate esters in the high molecular weight subcategory are not toxic by acute oral and dermal administration; LD50 values of all substances tested exceed the maximum amounts which can be administered to the animals. There are fewer data available on inhalation toxicity; only di-iso-nonyl phthalate (DINP) and di-iso-decyl phthalate (DIDP) have been tested. However, the phthalates in the high molecular weight subcategory have extremely low vapor pressures, and exposure by inhalation at potentially hazardous levels is not anticipated.</p> <p>Repeat dose toxicity. Several substances ranging from C8-C11 have been tested for repeated dose toxicity in studies ranging from 21 days to two years. Ditridecyl phthalate (CAS 119-06-2) has been studied by the Japan Ministry of Health and Welfare (unpublished report) and data for this substance is used as read-across data for DTDP*. In addition results from repeat dose studies examining DINP (CAS 685 15-48-0) and DIDP (CAS 68515-49-1) are used as read across for the di C9-C11 phthalates (CAS 68515-43-5). The principal effects found are those associated with peroxisomal proliferation, including liver enlargement and induction of peroxisomal enzymes. As shown for example in a comparative study of liver effects, the strongest inducers of peroxisomal proliferation were DEHP, DINP, and DIDP with substances of shorter and longer ester side chains (e.g., 610P*, 711P*, and diundecyl phthalate - DUP) showing less pronounced effects. Thus, it is reasonable to conclude that other members of this subcategory would show effects similar to but not more pronounced than those associated with DINP and DIDP. It should also be noted that the relevance of these findings to human health is, at best, questionable. It has been shown that these effects are mediated through the peroxisome proliferation-activated receptor alpha (PPARα), and that levels of PPARα are much higher in rodents than humans . Thus, one would expect humans to be substantially less responsive than rodents to peroxisome proliferating agents. Empirical evidence supporting this postulation is provided by studies in primates in which repeated administration of DEHP and DINP had no effects on liver, kidney or testicular parameters.</p> <p>In this regard it should also be noted that kidney enlargement is also commonly observed but normally without any pathological changes. There</p> |

is a component of the kidney changes which is also PPARa-related. It has also been shown that in male rats, DINP induces an alpha 2u-globulin nephropathy which is male rat- specific but without relevance to humans. Thus, as was true for the liver changes, the relevance of the kidney changes to human health is also questionable

Finally, some of the lower molecular weight phthalates can induce testicular atrophy when administered to juvenile rats at high levels. However, the higher molecular weight phthalates including di-n-octyl phthalate (DnOP), DINP, DIDP, 610P, and 71 1P do not induce testicular atrophy.

Further, the testis was not a target organ for DINP in either marmosets or cynomolgus monkeys. Thus, testicular atrophy is not an effect associated with phthalates in the high molecular weight subcategory

Reproductive toxicity: Reproductive toxicity tests in rats have been carried out with DINP, DIDP a linear C7-C9 phthalate (CAS 68515-41-3), a linear C9-C11 phthalate, and dinitridecyl phthalate (Japan Ministry of Health and Welfare, unpublished report). None of these affected fertility or profoundly affected male reproductive development. A slight decrease in offspring viability was reported for both DIDP and dinitridecyl phthalate at levels associated with maternal effects. DnOP was tested for effects on fertility in a continuous breeding protocol in mice, and, like the other members of this subcategory, did not reduce fertility. Thus, it can be concluded that the subcategory of high molecular weight phthalates do not affect fertility.

Developmental toxicity: Developmental toxicity tests in rats have been carried out with DINP; DIDP; C7-9 phthalate (CAS 68515-41-3); C9-11 phthalate (CAS 68515-43-5); and dinitridecyl phthalate (CAS 119-06-2). None of the substances tested affected litter size, foetal survival or bodyweight, and none produced teratogenic effects. Increased frequencies of developmental variants including dilated renal pelvis, and supernumerary lumbar and cervical ribs were found at levels associated with maternal effects. The toxicological significance of these developmental variants is unclear. DnOP was not teratogenic in mice when tested at very high levels. Thus, it can be concluded that this subcategory of high molecular weight phthalates do not produce profound developmental effects in rodents

Genotoxicity: The majority of the substances in the subcategory of high molecular weight phthalates have been tested for genetic activity in the Salmonella assay, and all were inactive. One large program covering many of these substances was carried out by the National Institute of Environmental Health Sciences. Similarly, a range of substances covering the majority of the carbon numbers in this subcategory were found to be inactive in mouse lymphoma tests

Chromosomal Aberrations. Two representative members of the subcategory of high molecular weight phthalates (DINP and DIDP) have been tested for chromosomal mutation in the mouse micronucleus test, and both were inactive. Dinitridecyl phthalate (CAS 119-06-2) induced neither structural chromosomal aberrations nor polyploidy in CHL cells up to the limit concentration of 4.75 mg/ml, in the absence or presence of an exogenous metabolic activation system (Japan Ministry of Health and Welfare, unpublished report). Further, all of the low molecular weight and transitional phthalates that have been tested were inactive.

*610P - mixed decyl, hexyl and octyl esters (CAS Rn: 68648-93-1)

*711P - C7,C11, branched and linear esters (CAS Rn: 111381-90-9)

* DTDP - di-C11-14, C13 rich ester (CAS 68515-47-9)

The material may produce peroxisome proliferation. Peroxisomes are single, membrane limited, cytoplasmic organelles that are found in the cells of animals, plants, fungi and protozoa. Peroxisome proliferators include certain hypolipidaemic drugs, phthalate ester plasticisers, industrial solvents, herbicides, food flavours, leukotriene D4 antagonists and hormones. Numerous studies in rats and mice have demonstrated the hepatocarcinogenic effects of peroxisome proliferators, and these compounds have been unequivocally established as carcinogens. However it is generally conceded that compounds inducing proliferation in rats and mice have little, if any, effect on human liver except at very high doses or extreme conditions of exposure.

4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI)

Inhalation (human) TCLo: 0.13 ppm/30 mins Eye (rabbit): 0.10 mg moderate

The substance is classified by IARC as Group 3:

NOT classifiable as to its carcinogenicity to humans.

Evidence of carcinogenicity may be inadequate or limited in animal testing.

The material may produce moderate eye irritation leading to inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

NAPHTHA PETROLEUM, LIGHT AROMATIC SOLVENT

Inhalation (rat) TCLo: 1320 ppm/6h/90D-I * [Devoe]

For C9 aromatics (typically trimethylbenzenes - TMBs)

Acute Toxicity

Acute toxicity studies (oral, dermal and inhalation routes of exposure) have been conducted in rats using various solvent products containing predominantly mixed C9 aromatic hydrocarbons (CAS RN 64742-95-6). Inhalation LC50 s range from 6,000 to 10,000 mg/m³ for C9 aromatic naphtha and 18,000 to 24,000 mg/m³ for 1,2,4 and 1,3,5-TMB, respectively. A rat oral LD50 reported for 1,2,4-TMB is 5 grams/kg bw and a rat dermal LD50 for the C9 aromatic naphtha is >4 ml/kg bw. These data indicate that C9 aromatic solvents show that LD50/LC50 values are greater than limit doses for acute toxicity studies established under OECD test guidelines.

Irritation and Sensitization

Several irritation studies, including skin, eye, and lung/respiratory system, have been conducted on members of the category. The results indicate that C9 aromatic hydrocarbon solvents are mildly to moderately irritating to the skin, minimally irritating to the eye, and have the potential to irritate the respiratory tract and cause depression of respiratory rates in mice. Respiratory irritation is a key endpoint in the current occupational exposure limits established for C9 aromatic hydrocarbon solvents and trimethylbenzenes. No evidence of skin sensitization was identified.

Repeated Dose Toxicity

Inhalation: The results from a subchronic (3 month) neurotoxicity study and a one-year chronic study (6 hr/day, 5 days/week) indicate that effects from inhalation exposure to C9 Aromatic Hydrocarbon Solvents on systemic toxicity are slight. A battery of neurotoxicity and neurobehavioral endpoints were evaluated in the 3-month inhalation study on C9 aromatic naphtha tested at concentrations of 0, 101, 452, or 1320 ppm (0, 500, 2,220, or 6,500 mg/m³). In this study, other than a transient weight reduction in the high exposure group (not statistically significant at termination of exposures), no effects were reported on neuropathology or neuro/behavioral parameters. The NOAEL for systemic and/or neurotoxicity was 6,500 mg/m³, the highest concentration tested. In an inhalation study of a commercial blend, rats were exposed to C9 aromatic naphtha concentrations of 0, 96, 198, or 373 ppm (0, 470, 970, 1830 mg/m³) for 6 hr/day, 5 days/week, for 12 months. Liver and kidney weights were increased in the high exposure group but no accompanying histopathology was observed in these organs.

The NOAEL was considered to be the high exposure level of 373 ppm, or 1830 mg/m³. In two subchronic rat inhalation studies, both of three months duration, rats were exposed to the individual TMB isomers (1,2,4-and 1,3,5-) to nominal concentrations of 0, 25, 100, or 250 ppm (0, 123, 492, or 1230 mg/m³). Respiratory irritation was observed at 492 (100 ppm) and 1230 mg/m³ (250 ppm) and no systemic toxicity was observed in either study. For both pure isomers, the NOELs are 25 ppm or 123 mg/m³ for respiratory irritation and 250 ppm or 1230 mg/m³ for systemic effects.

Oral: The C9 aromatic naphtha has not been tested via the oral route of exposure. Individual TMB isomers have been evaluated in a series of repeated-dose oral studies ranging from 14 days to 3 months over a wide range of doses. The effects observed in these studies included increased liver and kidney weights, changes in blood chemistry, increased salivation, and decreased weight gain at higher doses. Organ weight changes appeared to be adaptive as they were not accompanied by histopathological effects. Blood changes appeared sporadic and without pattern. One study reported hyaline droplet nephropathy in male rats at the highest dose (1000 mg/kg bw-day), an effect that is often associated with alpha-2mu-globulin-induced nephropathy and not considered relevant to humans. The doses at which effects were detected were 100 mg/kg-bw day or above (an exception was the pilot 14 day oral study - LOAEL 150 mg/kg bw-day - but the follow up three month study had a LOAEL of 600 mg/kg/bw-day with a NOAEL of 200 mg/kg bw-day). Since effects generally were not severe and could be considered adaptive or spurious, oral exposure does not appear to pose a high toxicity hazard for pure trimethylbenzene isomers.

Mutagenicity

In vitro genotoxicity testing of a variety of C9 aromatics has been conducted in both bacterial and mammalian cells. In vitro point mutation tests were conducted with Salmonella typhimurium and Escherichia coli bacterial strains, as well as with cultured mammalian cells such as the Chinese hamster cell ovary cells (HGPRT assay) with and without metabolic activation. In addition, several types of in vitro chromosomal aberration tests have been performed (chromosome aberration frequency in Chinese hamster ovary and lung cells, sister chromatid exchange in CHO cells). Results were negative both with and without metabolic activation for all category members. For the supporting chemical 1,2,3-TMB, a single in vitro chromosome aberration test was weakly positive. In vivo bone marrow cytogenetics test, rats were exposed to C9 aromatic

| | |
|--|---|
| | <p>naphtha at concentrations of 0, 153, 471, or 1540 ppm (0, 750, 2,310, or 7,560 mg/m³) 6 hr/day, for 5 days. No evidence of in vivo somatic cell genotoxicity was detected. Based on the cumulative results of these assays, genetic toxicity is unlikely for substances in the C9 Aromatic Hydrocarbon Solvents Category</p> <p>Reproductive and Developmental Toxicity</p> <p>Results from the three-generation reproduction inhalation study in rats indicate limited effects from C9 aromatic naphtha. In each of three generations (F0, F1 and F2), rats were exposed to High Flash Aromatic Naphtha (CAS RN 64742-95-6) via whole body inhalation at target concentrations of 0, 100, 500, or 1500 ppm (actual mean concentrations throughout the full study period were 0, 103, 495, or 1480 ppm, equivalent to 0, 505, 2430, or 7265 mg/m³, respectively). In each generation, both sexes were exposed for 10 weeks prior to and two weeks during mating for 6 hrs/day, 5 days/wks. Female rats in the F0, F1, and F2 generation were then exposed during gestation days 0-20 and lactation days 5-21 for 6 hrs/day, 7 days/wk. The age at exposure initiation differed among generations; F0 rats were exposed starting at 9 weeks of age, F1 exposure began at 5-7 weeks, and F2 exposure began at postnatal day (PND) 22. In the F0 and F1 parental generations, 30 rats/sex /group were exposed and mated. However, in the F2 generation, 40/sex/group were initially exposed due to concerns for toxicity, and 30/sex /group were randomly selected for mating, except that all survivors were used at 1480 ppm. F3 litters were not exposed directly and were sacrificed on lactation day 21.</p> <p>Systemic Effects on Parental Generations:</p> <p>The F0 males showed statistically and biologically significantly decreased mean body weight by ~15% at 1480 ppm when compared with controls. Seven females died or were sacrificed in extremis at 1480 ppm. The F0 female rats in the 495 ppm exposed group had a 13% decrease in body weight gain when adjusted for initial body weight when compared to controls. The F1 parents at 1480 ppm had statistically significantly decreased mean body weights (by ~13% (females) and 22% (males)), and locomotor activity. F1 parents at 1480 ppm had increased ataxia and mortality (six females). Most F2 parents (70/80) exposed to 1480 ppm died within the first week. The remaining animals survived throughout the rest of the exposure period. At week 4 and continuing through the study, F2 parents at 1480 ppm had statistically significant mean body weights much lower than controls (~33% for males; ~28% for females); body weights at 495 ppm were also reduced significantly (by 13% in males and 15% in females). The male rats in the 495 ppm exposed group had a 12% decrease in body weight gain when adjusted for initial body weight when compared to controls. Based on reduced body weight observed, the overall systemic toxicity LOAEC is 495 ppm (2430 mg/m³).</p> <p>Reproductive Toxicity-Effects on Parental Generations: There were no pathological changes noted in the reproductive organs of any animal of the F0, F1, or F2 generation. No effects were reported on sperm morphology, gestational period, number of implantation sites, or post-implantation loss in any generation. Also, there were no statistically or biologically significant differences in any of the reproductive parameters, including: number of mated females, copulatory index, copulatory interval, number of females delivering a litter, number of females delivering a live litter, or male fertility in the F0 or in the F2 generation. Male fertility was statistically significantly reduced at 1480 ppm in the F1 rats. However, male fertility was not affected in the F0 or in the F2 generations; therefore, the biological significance of this change is unknown and may or may not be attributed to the test substance. No reproductive effects were observed in the F0 or F1 dams exposed to 1480 ppm (7265 mg/m³). Due to excessive mortality at the highest concentration (1480 ppm, only six dams available) in the F2 generation, a complete evaluation is precluded. However, no clear signs of reproductive toxicity were observed in the F2 generation. Therefore, the reproductive NOAEC is considered 495 ppm (2430 mg/m³), which excludes analysis of the highest concentration due to excessive mortality.</p> <p>Developmental Toxicity - Effects on Pups: Because of significant maternal toxicity (including mortality) in dams in all generations at the highest concentration (1480 ppm), effects in offspring at 1480 ppm are not reported here. No significant effects were observed in the F1 and F2 generation offspring at 103 or 495 ppm. However, in F3 offspring, body weights and body weight gain were reduced by ~ 10-11% compared with controls at 495 ppm for approximately a week (PND 14 through 21). Maternal body weight was also depressed by ~ 12% throughout the gestational period compared with controls. The overall developmental LOAEC from this study is 495 ppm (2430 mg/m³) based on the body weights reductions observed in the F3 offspring.</p> <p>Conclusion: No effects on reproductive parameters were observed at any exposure concentration, although a confident assessment of the group exposed at the highest concentration was not possible. A potential developmental effect (reduction in mean pup weight and weight gain) was observed at a concentration that was also associated with maternal toxicity.</p> |
| 1,2,4-TRIMETHYL BENZENE | CHEMWATCH 2325 1,3,5-trimethylbenzene |
| 2,4'-DIPHENYLMETHANE DIISOCYANATE | No significant acute toxicological data identified in literature search. |
| NAPHTHALENE | <p>The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.</p> <p>WARNING: This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans.</p> |
| P-TOLUENESULFONYL ISOCYANATE | <p>for p-toluenesulfonyl isocyanate</p> <p>The acute oral toxicity (LD50) of PTSI is 2600 mg/kg. Based on the rapid hydrolysis of PTSI to PTSA (and carbon dioxide), repeated dose, reproductive, and developmental toxicity, as well as genotoxicity are best described by PTSA.</p> <p>.</p> <p>for p-toluenesulfonamide (PTSA):</p> <p>PTSA was studied for oral toxicity in rats in a single dose toxicity test at doses of 889, 1333, 2000 and 3000 mg/kg in females and 2000 mg/kg in males, and in an OECD combined repeat dose and reproductive/developmental toxicity screening test at doses of 0, 120, 300 and 750 mg/kg/day in both sexes .PTSA was also tested for mutagenicity with assays for reverse mutation in bacteria and chromosomal aberrations in cultured Chinese hamster (CHL) cells. The single dose toxicity test revealed LD50 values of above 2000 mg/kg for both sexes.</p> <p>For repeat dose toxicity caused, daily administration of 300 mg/kg or more in males and females displayed an increase in salivation and a reduction in body weight gain, as well as a suppression of food consumption. No compound-related deaths were observed. Haematuria was observed within 3 days administration of 750 mg/kg in 4/13 males. Hematological examination and blood chemistry measurements in males showed a decrease in white blood cell count with an increase in lymphocyte count, increases in blood urea nitrogen and chloride, and slight elevation in GOT in medium and high dose groups and a decrease in potassium concentration, and increased GPT levels in the high dose group. Histopathological examination showed cytoplasmic changes in the epithelium of the urinary bladder in both sexes and an accelerated involution in the thymus especially in females. Signs of toxicity, such as salivation and urinary bladder changes, were observed in animals given 120 mg/kg and above. The NOEL for repeat dose toxicity was less than 120 mg/kg/day. For reproductive/developmental toxicity, females given 750 mg/kg/day demonstrated possible delivery or lactation state dysfunction and developmental suppression of embryos. NOELs for reproductive performance and offspring development were both 300 mg/kg/day. No teratogenic effects were observed.</p> <p>The mutagenicity tests performed were all negative. PTSA was not mutagenic for bacteria either with or without an exogenous metabolic activation system up to 5000 ug/plate. No chromosomal aberrations or polyploidy were induced in CHL cells up to 1.7 mg/ml with metabolic activation and 1.3 mg/ml without metabolic activation.</p> |
| 1,3,5-TRIMETHYL BENZENE | CHEMWATCH 12171 1,2,4-trimethylbenzene |
| CALCIUM CARBONATE & 4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI) & 1,2,4-TRIMETHYL BENZENE & CALCIUM OXIDE & 2,4'-DIPHENYLMETHANE DIISOCYANATE & P-TOLUENESULFONYL ISOCYANATE & 1,3,5-TRIMETHYL BENZENE | <p>Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.</p> |

Duram 195 (Vertical and Self-Leveling)

| | |
|---|--|
| <p>CALCIUM CARBONATE & 1,3,5-TRIMETHYL BENZENE</p> | <p>The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.</p> |
| <p>4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI) & 2,4'-DIPHENYLMETHANE DIISOCYANATE</p> | <p>The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.</p> <p>for diisocyanates:</p> <p>In general, there appears to be little or no difference between aromatic and aliphatic diisocyanates as toxicants. In addition, there are insufficient data available to make any major distinctions between polymeric (<1000 MW) and monomeric diisocyanates. Based on repeated dose studies in animals by the inhalation route, both aromatic and aliphatic diisocyanates appear to be of high concern for pulmonary toxicity at low exposure levels. Based upon a very limited data set, it appears that diisocyanate prepolymers exhibit the same respiratory tract effects as the monomers in repeated dose studies. There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route. Most members of the diisocyanate category have not been tested for carcinogenic potential. Though the aromatic diisocyanates tested positive and the one aliphatic diisocyanate tested negative in one species, it is premature to make any generalizations about the carcinogenic potential of aromatic versus aliphatic diisocyanates. In the absence of more human data, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitizers. Diisocyanates are moderate to strong dermal sensitizers in animal studies. Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates.</p> <p>For monomers, effects on the respiratory tract (lungs and nasal cavities) were observed in animal studies at exposure concentrations of less than 0.005 mg/L. The experimental animal data available on prepolymeric diisocyanates show similar adverse effects at levels that range from 0.002 mg/L to 0.026 mg/L.</p> <p>There is also evidence that both aromatic and aliphatic diisocyanates are acutely toxic via the inhalation route</p> <p>Oncogenicity: Most members of the diisocyanate category have not been tested for carcinogenic potential. Commercially available Poly-MDI was tested in a 2-year inhalation study in rats. The tested material contained 47% aromatic 4,4'-methylenediphenyl diisocyanate (MDI) and 53% higher molecular weight oligomers. Interim sacrifices at one year showed that males and females in the highest dose group (6 mg/m³) had treatment related histological changes in the nasal cavity, lungs and mediastinal lymph nodes. The incidence and severity of degeneration and basal cell hyperplasia of the olfactory epithelium and Bowman's gland hyperplasia were increased in males at the mid and high doses and in females at the high dose following the two year exposure period. Pulmonary adenomas were found in 6 males and 2 females, and pulmonary adenocarcinoma in one male in the high dose group. However, aliphatic hexamethylene diisocyanate (HDI) was found not to be carcinogenic in a two year repeated dose study in rats by the inhalation route. HDI has not been tested in mice by the inhalation route.</p> <p>Though the oral route is not an expected route of exposure to humans, it should be noted that in two year repeated dose studies by the oral route, aromatic toluene diisocyanate (TDI) and 3,3'-dimethoxy-benzidine-4,4'-diisocyanate (dianisidine diisocyanate, DADI) were found to be carcinogenic in rodents. TDI induced a statistically significant increase in the incidence of liver tumors in rats and mice as well as dose-related hemangiosarcomas of the circulatory system and has been classified by the Agency as a B2 carcinogen. DADI was found to be carcinogenic in rats, but not in mice, with a statistically increase in the incidence of pancreatic tumors observed.</p> <p>Respiratory and Dermal Sensitization: Based on the available toxicity data in animals and epidemiologic studies of humans, aromatic diisocyanates such as TDI and MDI are strong respiratory sensitizers. Aliphatic diisocyanates are generally not active in animal models for respiratory sensitization. However, HDI and possibly isophorone diisocyanate (IPDI), are reported to be associated with respiratory sensitization in humans. Symptoms resulting from occupational exposure to HDI include shortness of breath, increased bronchoconstriction reaction to histamine challenges, asthmatic reactions, wheezing and coughing. Two case reports of human exposure to IPDI by inhalation suggest IPDI is a respiratory sensitizer in humans. In view of the information from case reports in humans, it would be prudent at this time to assume that both aromatic and aliphatic diisocyanates are respiratory sensitizers. Studies in both human and mice using TDI, HDI, MDI and dicyclohexylmethane-4,4'-diisocyanate (HMDI) suggest cross-reactivity with the other diisocyanates, irrespective of whether the challenge compound was an aliphatic or aromatic diisocyanate. Diisocyanates are moderate to strong dermal sensitizers in animal studies. There seems to be little or no difference in the level of reactivity between aromatic and aliphatic diisocyanates.</p> <p>Dermal Irritation: Skin irritation studies performed on rabbits and guinea pigs indicate no difference in the effects of aromatic versus aliphatic diisocyanates. The level of irritation ranged from slightly to severely irritating to the skin. One chemical, hydrogenated MDI (1,1-methylenbis-4-isocyanatocyclohexane), was found to be corrosive to the skin in guinea pigs.</p> |
| <p>4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI) & 2,4'-DIPHENYLMETHANE DIISOCYANATE & P-TOLUENESULFONYL ISOCYANATE</p> | <p>Allergic reactions which develop in the respiratory passages as bronchial asthma or rhinoconjunctivitis, are mostly the result of reactions of the allergen with specific antibodies of the IgE class and belong in their reaction rates to the manifestation of the immediate type. In addition to the allergen-specific potential for causing respiratory sensitisation, the amount of the allergen, the exposure period and the genetically determined disposition of the exposed person are likely to be decisive. Factors which increase the sensitivity of the mucosa may play a role in predisposing a person to allergy. They may be genetically determined or acquired, for example, during infections or exposure to irritant substances. Immunologically the low molecular weight substances become complete allergens in the organism either by binding to peptides or proteins (haptens) or after metabolism (prohaptens).</p> <p>Particular attention is drawn to so-called atopic diathesis which is characterised by an increased susceptibility to allergic rhinitis, allergic bronchial asthma and atopic eczema (neurodermatitis) which is associated with increased IgE synthesis.</p> <p>Exogenous allergic alveolitis is induced essentially by allergen specific immune-complexes of the IgG type; cell-mediated reactions (T lymphocytes) may be involved. Such allergy is of the delayed type with onset up to four hours following exposure.</p> <p>Isocyanate vapours/mists are irritating to the upper respiratory tract and lungs; the response may be severe enough to produce bronchitis with wheezing, gasping and severe distress, even sudden loss of consciousness, and pulmonary oedema. Possible neurological symptoms arising from isocyanate exposure include headache, insomnia, euphoria, ataxia, anxiety neurosis, depression and paranoia. Gastrointestinal disturbances are characterised by nausea and vomiting. Pulmonary sensitisation may produce asthmatic reactions ranging from minor breathing difficulties to severe allergic attacks; this may occur following a single acute exposure or may develop without warning after a period of tolerance. A respiratory response may occur following minor skin contact. Skin sensitisation is possible and may result in allergic dermatitis responses including rash, itching, hives and swelling of extremities.</p> <p>Isocyanate-containing vapours/ mists may cause inflammation of eyes and nasal passages.</p> <p>Onset of symptoms may be immediate or delayed for several hours after exposure. Sensitised people can react to very low levels of airborne isocyanates. Unprotected or sensitised persons should not be allowed to work in situations allowing exposure to this material.</p> |
| <p>SOLVENT NAPHTHA PETROLEUM, HEAVY AROMATIC & NAPHTHA PETROLEUM, LIGHT AROMATIC SOLVENT & NAPHTHA PETROLEUM, HEAVY ALKYLATE</p> | <p>Studies indicate that normal, branched and cyclic paraffins are absorbed from the mammalian gastrointestinal tract and that the absorption of n-paraffins is inversely proportional to the carbon chain length, with little absorption above C30. With respect to the carbon chain lengths likely to be present in mineral oil, n-paraffins may be absorbed to a greater extent than iso- or cyclo-paraffins.</p> <p>The major classes of hydrocarbons have been shown to be well absorbed by the gastrointestinal tract in various species. In many cases, the hydrophobic hydrocarbons are ingested in association with dietary lipids. The dependence of hydrocarbon absorption on concomitant triglyceride digestion and absorption, is known as the "hydrocarbon continuum hypothesis", and asserts that a series of solubilising phases in the intestinal lumen, created by dietary triglycerides and their digestion products, afford hydrocarbons a route to the lipid phase of the intestinal absorptive cell (enterocyte) membrane. While some hydrocarbons may traverse the mucosal epithelium unmetabolised and appear as solutes in lipoprotein particles in intestinal lymph, there is evidence that most hydrocarbons partially separate from nutrient lipids and undergo metabolic transformation in the enterocyte. The enterocyte may play a major role in determining the proportion of an absorbed hydrocarbon that, by escaping initial biotransformation, becomes available for deposition in its unchanged form in peripheral tissues such as adipose tissue, or in the liver.</p> <p>For petroleum: This product contains benzene, which can cause acute myeloid leukaemia, and n-hexane, which can be metabolized to compounds which are toxic to the nervous system. This product contains toluene, and animal studies suggest high concentrations of toluene lead to hearing loss. This product contains ethyl benzene and naphthalene, from which animal testing shows evidence of tumour formation.</p> |

Cancer-causing potential: Animal testing shows inhaling petroleum causes tumours of the liver and kidney; these are however not considered to be relevant in humans.

Mutation-causing potential: Most studies involving gasoline have returned negative results regarding the potential to cause mutations, including all recent studies in living human subjects (such as in petrol service station attendants).

Reproductive toxicity: Animal studies show that high concentrations of toluene (>0.1%) can cause developmental effects such as lower birth weight and developmental toxicity to the nervous system of the foetus. Other studies show no adverse effects on the foetus.

Human effects: Prolonged or repeated contact may cause defatting of the skin which can lead to skin inflammation and may make the skin more susceptible to irritation and penetration by other materials.

Animal testing shows that exposure to gasoline over a lifetime can cause kidney cancer, but the relevance in humans is questionable.

For Low Boiling Point Naphthas (LBPNS):

Acute toxicity:

LBPNS generally have low acute toxicity by the oral (median lethal dose [LD50] in rats > 2000 mg/kg-bw), inhalation (LD50 in rats > 5000 mg/m3) and dermal (LD50 in rabbits > 2000 mg/kg-bw) routes of exposure

Most LBPNS are mild to moderate eye and skin irritants in rabbits, with the exception of heavy catalytic cracked and heavy catalytic reformed naphthas, which have higher primary skin irritation indices.

Sensitisation:

LBPNS do not appear to be skin sensitizers, but a poor response in the positive control was also noted in these studies

Repeat dose toxicity:

The lowest-observed-adverse-effect concentration (LOAEC) and lowest-observed-adverse-effect level (LOAEL) values identified following short-term (2-89 days) and subchronic (greater than 90 days) exposure to the LBPNS substances. These values were determined for a variety of endpoints after considering the toxicity data for all LBPNS in the group. Most of the studies were carried out by the inhalation route of exposure. Renal effects, including increased kidney weight, renal lesions (renal tubule dilation, necrosis) and hyaline droplet formation, observed in male rats exposed orally or by inhalation to most LBPNS, were considered species- and sex-specific These effects were determined to be due to a mechanism of action not relevant to humans -specifically, the interaction between hydrocarbon metabolites and alpha-2-microglobulin, an enzyme not produced in substantial amounts in female rats, mice and other species, including humans. The resulting nephrotoxicity and subsequent carcinogenesis in male rats were therefore not considered in deriving LOAEC/LOAEL values.

Only a limited number of studies of short-term and subchronic duration were identified for site-restricted LBPNS. The lowest LOAEC identified in these studies, via the inhalation route, is 5475 mg/m3, based on a concentration-related increase in liver weight in both male and female rats following a 13-week exposure to light catalytic cracked naphtha. Shorter exposures of rats to this test substance resulted in nasal irritation at 9041 mg/m3

No systemic toxicity was reported following dermal exposure to light catalytic cracked naphtha, but skin irritation and accompanying histopathological changes were increased, in a dose-dependent manner, at doses as low as 30 mg/kg-bw per day when applied 5 days per week for 90 days in rats

No non-cancer chronic toxicity studies (= 1 year) were identified for site-restricted LBPNS and very few non-cancer chronic toxicity studies were identified for other LBPNS. An LOAEC of 200 mg/m3 was noted in a chronic inhalation study that exposed mice and rats to unleaded gasoline (containing 2% benzene). This inhalation LOAEC was based on ocular discharge and ocular irritation in rats. At the higher concentration of 6170 mg/m3, increased kidney weight was observed in male and female rats (increased kidney weight was also observed in males only at 870 mg/m3). Furthermore, decreased body weight in male and female mice was also observed at 6170 mg/m3

A LOAEL of 714 mg/kg-bw was identified for dermal exposure based on local skin effects (inflammatory and degenerative skin changes) in mice following application of naphtha for 105 weeks. No systemic toxicity was reported.

Genotoxicity:

Although few genotoxicity studies were identified for the site-restricted LBPNS, the genotoxicity of several other LBPNS substances has been evaluated using a variety of in vivo and in vitro assays. While in vivo genotoxicity assays were negative overall, the in vitro tests exhibited mixed results.

For in vivo genotoxicity tests, LBPNS exhibited negative results for chromosomal aberrations and micronuclei induction, but exhibited positive results in one sister chromatid exchange assay although this result was not considered definitive for clastogenic activity as no genetic material was unbalanced or lost. Mixtures that were tested, which included a number of light naphthas, displayed mixed results (i.e., both positive and negative for the same assay) for chromosomal aberrations and negative results for the dominant lethal mutation assay. Unleaded gasoline (containing 2% benzene) was tested for its ability to induce unscheduled deoxyribonucleic acid (DNA) synthesis (UDS) and replicative DNA synthesis (RDS) in rodent hepatocytes and kidney cells. UDS and RDS were induced in mouse hepatocytes via oral exposure and RDS was induced in rat kidney cells via oral and inhalation exposure. Unleaded gasoline (benzene content not stated) exhibited negative results for chromosomal aberrations and the dominant lethal mutation assay and mixed results for atypical cell foci in rodent renal and hepatic cells.

For in vitro genotoxicity studies, LBPNS were negative for six out of seven Ames tests, and were also negative for UDS and for forward mutations LBPNS exhibited mixed or equivocal results for the mouse lymphoma and sister chromatid exchange assays, as well as for cell transformation and positive results for one bacterial DNA repair assay. Mixtures that were tested, which included a number of light naphthas, displayed negative results for the Ames and mouse lymphoma assays Gasoline exhibited negative results for the Ames test battery, the sister chromatid exchange assay and for one mutagenicity assay. Mixed results were observed for UDS and the mouse lymphoma assay.

While the majority of in vivo genotoxicity results for LBPNS substances are negative, the potential for genotoxicity of LBPNS as a group cannot be discounted based on the mixed in vitro genotoxicity results.

Carcinogenicity:

Although a number of epidemiological studies have reported increases in the incidence of a variety of cancers, the majority of these studies are considered to contain incomplete or inadequate information. Limited data, however, are available for skin cancer and leukemia incidence, as well as mortality among petroleum refinery workers. It was concluded that there is limited evidence supporting the view that working in petroleum refineries entails a carcinogenic risk (Group 2A carcinogen). IARC (1989a) also classified gasoline as a Group 2B carcinogen; it considered the evidence for carcinogenicity in humans from gasoline to be inadequate and noted that published epidemiological studies had several limitations, including a lack of exposure data and the fact that it was not possible to separate the effects of combustion products from those of gasoline itself. Similar conclusions were drawn from other reviews of epidemiological studies for gasoline (US EPA 1987a, 1987b). Thus, the evidence gathered from these epidemiological studies is considered to be inadequate to conclude on the effect of human exposure to LBPNS substances.

No inhalation studies assessing the carcinogenicity of the site-restricted LBPNS were identified. Only unleaded gasoline has been examined for its carcinogenic potential, in several inhalation studies. In one study, rats and mice were exposed to 0, 200, 870 or 6170 mg/m3 of a 2% benzene formulation of the test substance, via inhalation, for approximately 2 years. A statistically significant increase in hepatocellular adenomas and carcinomas, as well as a non-statistical increase in renal tumours, were observed at the highest dose in female mice. A dose-dependent increase in the incidence of primary renal neoplasms was also detected in male rats, but this was not considered to be relevant to humans, as discussed previously. Carcinogenicity was also assessed for unleaded gasoline, via inhalation, as part of initiation/promotion studies. In these studies, unleaded gasoline did not appear to initiate tumour formation, but did show renal cell and hepatic tumour promotion ability, when rats and mice were exposed, via inhalation, for durations ranging from 13 weeks to approximately 1 year using an initiation/promotion protocol However, further examination of data relevant to the composition of unleaded gasoline demonstrated that this is a highly-regulated substance; it is expected to contain a lower percentage of benzene and has a discrete component profile when compared to other substances in the LBPNS group.

Both the European Commission and the International Agency for Research on Cancer (IARC) have classified LBPNS substances as carcinogenic. All of these substances were classified by the European Commission (2008) as Category 2 (R45: may cause cancer) (benzene content = 0.1% by weight). IARC has classified gasoline, an LBPNS, as a Group 2B carcinogen (possibly carcinogenic to humans) and "occupational exposures in petroleum refining" as Group 2A carcinogens (probably carcinogenic to humans).

Several studies were conducted on experimental animals to investigate the dermal carcinogenicity of LBPNS. The majority of these studies were conducted through exposure of mice to doses ranging from 694-1351 mg/kg-bw, for durations ranging from 1 year to the animals lifetime or until a tumour persisted for 2 weeks. Given the route of exposure, the studies specifically examined the formation of skin tumours. Results for carcinogenicity via dermal exposure are mixed. Both malignant and benign skin tumours were induced with heavy catalytic cracked naphtha, light catalytic cracked naphtha, light

**NAPHTHA PETROLEUM,
LIGHT AROMATIC SOLVENT &
NAPHTHA PETROLEUM,
HEAVY ALKYLATE**

| | | | |
|---|---|--|----------|
| | <p>straight-run naphtha and naphtha Significant increases in squamous cell carcinomas were also observed when mice were dermally treated with Stoddard solvent, but the latter was administered as a mixture (90% test substance), and the details of the study were not available. In contrast, insignificant increases in tumour formation or no tumours were observed when light alkylate naphtha, heavy catalytic reformed naphtha, sweetened naphtha, light catalytically cracked naphtha or unleaded gasoline was dermally applied to mice. Negative results for skin tumours were also observed in male mice dermally exposed to sweetened naphtha using an initiation/promotion protocol.</p> <p>Reproductive/ Developmental toxicity: No reproductive or developmental toxicity was observed for the majority of LBP substances evaluated. Most of these studies were carried out by inhalation exposure in rodents.</p> <p>NOAEC values for reproductive toxicity following inhalation exposure ranged from 1701 mg/m³ (CAS RN 8052-41-3) to 27 687 mg/m³ (CAS RN 64741-63-5) for the LBPNs group evaluated, and from 7690 mg/m³ to 27 059 mg/m³ for the site-restricted light catalytic cracked and full-range catalytic reformed naphthas. However, a decreased number of pups per litter and higher frequency of post-implantation loss were observed following inhalation exposure of female rats to hydrotreated heavy naphtha (CAS RN 64742-48-9) at a concentration of 4679 mg/m³, 6 hours per day, from gestational days 7-20. For dermal exposures, NOAEL values of 714 mg/kg-bw (CAS RN 8030-30-6) and 1000 mg/kg-bw per day (CAS RN 68513-02-0) were noted. For oral exposures, no adverse effects on reproductive parameters were reported when rats were given site-restricted light catalytic cracked naphtha at 2000 mg/kg on gestational day 13.</p> <p>For most LBPNs, no treatment-related developmental effects were observed by the different routes of exposure. However, developmental toxicity was observed for a few naphthas. Decreased foetal body weight and an increased incidence of ossification variations were observed when rat dams were exposed to light aromatized solvent naphtha, by gavage, at 1250 mg/kg-bw per day. In addition, pregnant rats exposed by inhalation to hydrotreated heavy naphtha at 4679 mg/m³ delivered pups with higher birth weights. Cognitive and memory impairments were also observed in the offspring.</p> <p>Low Boiling Point Naphthas [Site-Restricted]</p> | | |
| <p>NAPHTHA PETROLEUM, LIGHT AROMATIC SOLVENT & 1,2,4-TRIMETHYL BENZENE & 1,3,5-TRIMETHYL BENZENE</p> | <p>For trimethylbenzenes: Absorption of 1,2,4-trimethylbenzene occurs after oral, inhalation, or dermal exposure. Occupationally, inhalation and dermal exposures are the most important routes of absorption although systemic intoxication from dermal absorption is not likely to occur due to the dermal irritation caused by the chemical prompting quick removal. Following oral administration of the chemical to rats, 62.6% of the dose was recovered as urinary metabolites indicating substantial absorption. 1,2,4-Trimethylbenzene is lipophilic and may accumulate in fat and fatty tissues. In the blood stream, approximately 85% of the chemical is bound to red blood cells. Metabolism occurs by side-chain oxidation to form alcohols and carboxylic acids which are then conjugated with glucuronic acid, glycine, or sulfates for urinary excretion. After a single oral dose to rats of 1200 mg/kg, urinary metabolites consisted of approximately 43.2% glycine, 6.6% glucuronic, and 12.9% sulfuric acid conjugates. The two principle metabolites excreted by rabbits after oral administration of 438 mg/kg/day for 5 days were 2,4-dimethylbenzoic acid and 3,4-dimethylhippuric acid. The major routes of excretion of 1,2,4-trimethylbenzene are exhalation of parent compound and elimination of urinary metabolites. Half-times for urinary metabolites were reported as 9.5 hours for glycine, 22.9 hours for glucuronide, and 37.6 hours for sulfuric acid conjugates.</p> <p>Acute Toxicity Direct contact with liquid 1,2,4-trimethylbenzene is irritating to the skin and breathing the vapor is irritating to the respiratory tract causing pneumonitis. Breathing high concentrations of the chemical vapor causes headache, fatigue, and drowsiness. In humans liquid 1,2,4-trimethylbenzene is irritating to the skin and inhalation of vapor causes chemical pneumonitis. High concentrations of vapor (5000-9000 ppm) cause headache, fatigue, and drowsiness. The concentration of 5000 ppm is roughly equivalent to a total of 221 mg/kg assuming a 30 minute exposure period (see end note 1). 2. Animals - Mice exposed to 8130-9140 ppm 1,2,4-trimethylbenzene (no duration given) had loss of righting response and loss of reflexes. Direct dermal contact with the chemical (no species given) causes vasodilation, erythema, and irritation (U.S. EPA). Seven of 10 rats died after an oral dose of 2.5 mL of a mixture of trimethylbenzenes in olive oil (average dose approximately 4.4 g/kg). Rats and mice were exposed by inhalation to a coal tar distillate containing about 70% 1,3,5- and 1,2,4-trimethylbenzene; no pathological changes were noted in either species after exposure to 1800-2000 ppm for up to 48 continuous hours, or in rats after 14 exposures of 8 hours each at the same exposure levels. No effects were reported for rats exposed to a mixture of trimethylbenzenes at 1700 ppm for 10 to 21 days.</p> <p>Neurotoxicity 1,2,4-Trimethylbenzene depresses the central nervous system. Exposure to solvent mixtures containing the chemical causes headache, fatigue, nervousness, and drowsiness. Occupationally, workers exposed to a solvent containing 50% 1,2,4-trimethylbenzene had nervousness, headaches, drowsiness, and vertigo (U.S. EPA). Headache, fatigue, and drowsiness were reported for workers exposed (no dose given) to paint thinner containing 80% 1,2,4- and 1,3,5-trimethylbenzenes.</p> <p>Results of the developmental toxicity study indicate that the C9 fraction caused adverse neurological effects at the highest dose (1500 ppm) tested.</p> <p>Subchronic/Chronic Toxicity Long-term exposure to solvents containing 1,2,4-trimethylbenzene may cause nervousness, tension, and bronchitis. Painters that worked for several years with a solvent containing 50% 1,2,4- and 30% 1,3,5-trimethylbenzene showed nervousness, tension and anxiety, asthmatic bronchitis, anemia, and alterations in blood clotting; haematological effects may have been due to trace amounts of benzene.</p> <p>Rats given 1,2,4-trimethylbenzene orally at doses of 0.5 or 2.0 g/kg/day, 5 days/week for 4 weeks. All rats exposed to the high dose died and 1 rat in the low dose died (no times given); no other effects were reported. Rats exposed by inhalation to 1700 ppm of a trimethylbenzene isomeric mixture for 4 months had decreased weight gain, lymphopenia and neutrophilia.</p> <p>Genotoxicity: Results of mutagenicity testing, indicate that the C9 fraction does not induce gene mutations in prokaryotes (Salmonella typhimurium/mammalian microsome assay); or in mammalian cells in culture (in Chinese hamster ovary cells with and without activation). The C9 fraction does not induce chromosome mutations in Chinese hamster ovary cells with and without activation; does not induce chromosome aberrations in the bone marrow of Sprague-Dawley rats exposed by inhalation (6 hours/day for 5 days); and does not induce sister chromatid exchange in Chinese hamster ovary cells with and without activation.</p> <p>Developmental/Reproductive Toxicity: A three-generation reproductive study on the C9 fraction was conducted CD rats (30/sex/group) were exposed by inhalation to the C9 fraction at concentrations of 0, 100, 500, or 1500 ppm (0, 100, 500, or 1500 mg/kg/day) for 6 hours/day, 5 days/week. There was evidence of parental and reproductive toxicity at all dose levels. Indicators of parental toxicity included reduced body weights, increased salivation, hunched posture, aggressive behavior, and death. Indicators of adverse reproductive system effects included reduced litter size and reduced pup body weight. The LOEL was 100 ppm; a no-observed-effect level was not established. Developmental toxicity, including possible developmental neurotoxicity, was evident in rats in a 3-generation reproductive study.</p> <p>No effects on fecundity or fertility occurred in rats treated dermally with up to 0.3 mL/rat/day of a mixture of trimethylbenzenes, 4-6 hours/day, 5 days/week over one generation.</p> | | |
| <p>1,2,4-TRIMETHYL BENZENE & 1,3,5-TRIMETHYL BENZENE</p> | <p>Other Toxicity data is available for CHEMWATCH 12172 1,2,3-trimethylbenzene</p> | | |
| <p>NAPHTHALENE & 1,3,5-TRIMETHYL BENZENE</p> | <p>The material may be irritating to the eye, with prolonged contact causing inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.</p> | | |
| <p>Acute Toxicity</p> | <p>✗</p> | <p>Carcinogenicity</p> | <p>✓</p> |
| <p>Skin Irritation/Corrosion</p> | <p>✓</p> | <p>Reproductivity</p> | <p>✓</p> |
| <p>Serious Eye Damage/Irritation</p> | <p>✓</p> | <p>STOT - Single Exposure</p> | <p>✓</p> |
| <p>Respiratory or Skin sensitisation</p> | <p>✓</p> | <p>STOT - Repeated Exposure</p> | <p>✗</p> |
| <p>Mutagenicity</p> | <p>✗</p> | <p>Aspiration Hazard</p> | <p>✗</p> |

Legend: ✗ – Data either not available or does not fill the criteria for classification
 ✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity

| | | | | | |
|---|-----------------|---------------------------|-------------------------------|------------------|---------------|
| Duram 195 (Vertical and Self-Leveling) | Endpoint | Test Duration (hr) | Species | Value | Source |
| | Not Available | Not Available | Not Available | Not Available | Not Available |
| calcium carbonate | Endpoint | Test Duration (hr) | Species | Value | Source |
| | NOEC(ECx) | 1h | Fish | 4-320mg/l | 4 |
| | LC50 | 96h | Fish | >165200mg/L | 4 |
| | EC50 | 72h | Algae or other aquatic plants | >14mg/l | 2 |
| diisononyl phthalate | Endpoint | Test Duration (hr) | Species | Value | Source |
| | NOEC(ECx) | 504h | Crustacea | >0.034mg/l | 1 |
| | LC50 | 96h | Fish | >0.1mg/l | 2 |
| | EC50 | 72h | Algae or other aquatic plants | >88mg/l | 2 |
| | EC50 | 96h | Algae or other aquatic plants | >2.8mg/l | 1 |
| | EC50 | 48h | Crustacea | >0.086mg/l | 1 |
| 4,4'-diphenylmethane diisocyanate (MDI) | Endpoint | Test Duration (hr) | Species | Value | Source |
| | LC50 | 96h | Fish | 95.24-134.37mg/l | Not Available |
| | BCF | 672h | Fish | 61-150 | 7 |
| | EC50 | 48h | Crustacea | >100mg/l | 2 |
| solvent naphtha petroleum, heavy aromatic | Endpoint | Test Duration (hr) | Species | Value | Source |
| | EC50(ECx) | 48h | Crustacea | 0.95mg/l | 1 |
| | EC50 | 72h | Algae or other aquatic plants | <1mg/l | 1 |
| | LC50 | 96h | Fish | 2-5mg/l | Not Available |
| | EC50 | 96h | Algae or other aquatic plants | 11.7mg/l | 2 |
| naphtha petroleum, light aromatic solvent | Endpoint | Test Duration (hr) | Species | Value | Source |
| | NOEC(ECx) | 72h | Algae or other aquatic plants | 1mg/l | 1 |
| | EC50 | 72h | Algae or other aquatic plants | 19mg/l | 1 |
| | EC50 | 96h | Algae or other aquatic plants | 64mg/l | 2 |
| | EC50 | 48h | Crustacea | 6.14mg/l | 1 |
| 1,2,4-trimethyl benzene | Endpoint | Test Duration (hr) | Species | Value | Source |
| | BCF | 1344h | Fish | 31-207 | 7 |
| | EC50(ECx) | 96h | Algae or other aquatic plants | 2.356mg/l | 2 |
| | EC50 | 96h | Algae or other aquatic plants | 2.356mg/l | 2 |
| | EC50 | 48h | Crustacea | ca.6.14mg/l | 1 |
| | LC50 | 96h | Fish | 3.41mg/l | 2 |
| calcium oxide | Endpoint | Test Duration (hr) | Species | Value | Source |
| | LC50 | 96h | Fish | 50.6mg/l | 2 |
| | EC50 | 72h | Algae or other aquatic plants | >14mg/l | 2 |
| | EC50 | 48h | Crustacea | 49.1mg/l | 2 |
| 2,4'-diphenylmethane diisocyanate | Endpoint | Test Duration (hr) | Species | Value | Source |
| | NOEC(ECx) | 504h | Crustacea | >=10mg/l | 2 |
| naphthalene | Endpoint | Test Duration (hr) | Species | Value | Source |
| | BCF | 1344h | Fish | 23-146 | 7 |
| | EC50(ECx) | 0.05h | Crustacea | <0.000001mg/l | 4 |
| | EC50 | 72h | Algae or other aquatic plants | ca.0.4mg/l | 1 |
| | EC50 | 48h | Crustacea | 1.09-3.4mg/l | 4 |
| | LC50 | 96h | Fish | 0.213mg/l | 4 |

Duram 195 (Vertical and Self-Leveling)

| naphtha petroleum, heavy alkylate | Endpoint | Test Duration (hr) | Species | Value | Source |
|-----------------------------------|-----------|-------------------------------|-------------------------------|---------|--------|
| | NOEC(ECx) | 72h | Algae or other aquatic plants | 0.1mg/l | 1 |
| EC50 | 72h | Algae or other aquatic plants | 13mg/l | 1 | |

| p-toluenesulfonyl isocyanate | Endpoint | Test Duration (hr) | Species | Value | Source |
|------------------------------|-----------|--------------------|-------------------------------|----------|--------|
| | NOEC(ECx) | 72h | Algae or other aquatic plants | 10mg/l | 2 |
| | LC50 | 96h | Fish | >45mg/l | 2 |
| | EC50 | 72h | Algae or other aquatic plants | 25mg/l | 2 |
| | EC50 | 48h | Crustacea | >100mg/l | 2 |

| 1,3,5-trimethyl benzene | Endpoint | Test Duration (hr) | Species | Value | Source |
|-------------------------|-----------|--------------------|-------------------------------|-----------|--------|
| | BCF | 1680h | Fish | 23-342 | 7 |
| | LC50 | 96h | Fish | 5.216mg/l | 2 |
| | EC50 | 48h | Crustacea | 13mg/L | 5 |
| | NOEC(ECx) | 384h | Crustacea | 0.257mg/l | 2 |
| | EC50 | 96h | Algae or other aquatic plants | 3.084mg/l | 2 |

Legend: *Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data*

Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.

Wastes resulting from use of the product must be disposed of on site or at approved waste sites.

DO NOT discharge into sewer or waterways.

Persistence and degradability

| Ingredient | Persistence: Water/Soil | Persistence: Air |
|---|-----------------------------|-----------------------------|
| diisononyl phthalate | HIGH | HIGH |
| 4,4'-diphenylmethane diisocyanate (MDI) | LOW (Half-life = 1 days) | LOW (Half-life = 0.24 days) |
| 1,2,4-trimethyl benzene | LOW (Half-life = 56 days) | LOW (Half-life = 0.67 days) |
| 2,4'-diphenylmethane diisocyanate | HIGH | HIGH |
| naphthalene | HIGH (Half-life = 258 days) | LOW (Half-life = 1.23 days) |
| p-toluenesulfonyl isocyanate | HIGH | HIGH |
| 1,3,5-trimethyl benzene | HIGH | HIGH |

Bioaccumulative potential

| Ingredient | Bioaccumulation |
|---|------------------------|
| diisononyl phthalate | LOW (BCF = 183.8) |
| 4,4'-diphenylmethane diisocyanate (MDI) | LOW (BCF = 15) |
| solvent naphtha petroleum, heavy aromatic | LOW (BCF = 159) |
| 1,2,4-trimethyl benzene | LOW (BCF = 275) |
| 2,4'-diphenylmethane diisocyanate | HIGH (LogKOW = 5.4481) |
| naphthalene | HIGH (BCF = 18000) |
| p-toluenesulfonyl isocyanate | LOW (LogKOW = 2.3424) |
| 1,3,5-trimethyl benzene | LOW (BCF = 342) |

Mobility in soil

| Ingredient | Mobility |
|---|--------------------|
| diisononyl phthalate | LOW (KOC = 467200) |
| 4,4'-diphenylmethane diisocyanate (MDI) | LOW (KOC = 376200) |
| 1,2,4-trimethyl benzene | LOW (KOC = 717.6) |
| 2,4'-diphenylmethane diisocyanate | LOW (KOC = 384000) |
| naphthalene | LOW (KOC = 1837) |
| p-toluenesulfonyl isocyanate | LOW (KOC = 882.1) |
| 1,3,5-trimethyl benzene | LOW (KOC = 703) |

SECTION 13 Disposal considerations

Waste treatment methods

| | |
|-------------------------------------|---|
| Product / Packaging disposal | <ul style="list-style-type: none"> ▶ Containers may still present a chemical hazard/ danger when empty. ▶ Return to supplier for reuse/ recycling if possible. <p>Otherwise:</p> <ul style="list-style-type: none"> ▶ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product. <p>Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.</p> <p>A Hierarchy of Controls seems to be common - the user should investigate:</p> <ul style="list-style-type: none"> ▶ Reduction ▶ Reuse ▶ Recycling ▶ Disposal (if all else fails) <p>This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.</p> <ul style="list-style-type: none"> ▶ DO NOT allow wash water from cleaning or process equipment to enter drains. ▶ It may be necessary to collect all wash water for treatment before disposal. ▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ▶ Where in doubt contact the responsible authority. ▶ DO NOT recycle spilled material. ▶ Consult State Land Waste Management Authority for disposal. ▶ Neutralise spill material carefully and decontaminate empty containers and spill residues with 10% ammonia solution plus detergent or a proprietary decontaminant prior to disposal. ▶ DO NOT seal or stopper drums being decontaminated as CO2 gas is generated and may pressurise containers. ▶ Puncture containers to prevent re-use. ▶ Bury or incinerate residues at an approved site. |
|-------------------------------------|---|

SECTION 14 Transport information

Labels Required

| | |
|---------------------------|---|
| COMBUSTIBLE LIQUID | COMBUSTIBLE LIQUID, regulated for storage purposes only |
| Marine Pollutant | NO |
| HAZCHEM | Not Applicable |

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

| Product name | Group |
|---|---------------|
| calcium carbonate | Not Available |
| diisononyl phthalate | Not Available |
| 4,4'-diphenylmethane diisocyanate (MDI) | Not Available |
| solvent naphtha petroleum, heavy aromatic | Not Available |
| naphtha petroleum, light aromatic solvent | Not Available |
| 1,2,4-trimethyl benzene | Not Available |
| calcium oxide | Not Available |
| 2,4'-diphenylmethane diisocyanate | Not Available |
| naphthalene | Not Available |
| naphtha petroleum, heavy alkylate | Not Available |
| p-toluenesulfonyl isocyanate | Not Available |
| 1,3,5-trimethyl benzene | Not Available |

Transport in bulk in accordance with the IGC Code

| Product name | Ship Type |
|---|---------------|
| calcium carbonate | Not Available |
| diisononyl phthalate | Not Available |
| 4,4'-diphenylmethane diisocyanate (MDI) | Not Available |

Duram 195 (Vertical and Self-Leveling)

| Product name | Ship Type |
|---|---------------|
| solvent naphtha petroleum, heavy aromatic | Not Available |
| naphtha petroleum, light aromatic solvent | Not Available |
| 1,2,4-trimethyl benzene | Not Available |
| calcium oxide | Not Available |
| 2,4'-diphenylmethane diisocyanate | Not Available |
| naphthalene | Not Available |
| naphtha petroleum, heavy alkylate | Not Available |
| p-toluenesulfonyl isocyanate | Not Available |
| 1,3,5-trimethyl benzene | Not Available |

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

calcium carbonate is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

diisononyl phthalate is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

4,4'-diphenylmethane diisocyanate (MDI) is found on the following regulatory lists

Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

solvent naphtha petroleum, heavy aromatic is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

naphtha petroleum, light aromatic solvent is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Not Classified as Carcinogenic

1,2,4-trimethyl benzene is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australian Inventory of Industrial Chemicals (AIIC)

calcium oxide is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

2,4'-diphenylmethane diisocyanate is found on the following regulatory lists

Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

naphthalene is found on the following regulatory lists

Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 10 / Appendix C

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

naphtha petroleum, heavy alkylate is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

p-toluenesulfonyl isocyanate is found on the following regulatory lists

Australia Model Work Health and Safety Regulations - Hazardous chemicals (other than lead) requiring health monitoring

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

1,3,5-trimethyl benzene is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australian Inventory of Industrial Chemicals (AIIC)

National Inventory Status

| National Inventory | Status |
|------------------------------|--------|
| Australia - AIIC / Australia | Yes |

| National Inventory | Status |
|-------------------------------|--|
| Non-Industrial Use | |
| Canada - DSL | Yes |
| Canada - NDSL | No (diisononyl phthalate; 4,4'-diphenylmethane diisocyanate (MDI); solvent naphtha petroleum, heavy aromatic; naphtha petroleum, light aromatic solvent; 1,2,4-trimethyl benzene; calcium oxide; 2,4'-diphenylmethane diisocyanate; naphthalene; naphtha petroleum, heavy alkylate; p-toluenesulfonyl isocyanate; 1,3,5-trimethyl benzene) |
| China - IECSC | Yes |
| Europe - EINEC / ELINCS / NLP | Yes |
| Japan - ENCS | No (naphtha petroleum, heavy alkylate) |
| Korea - KECI | Yes |
| New Zealand - NZIoC | Yes |
| Philippines - PICCS | Yes |
| USA - TSCA | Yes |
| Taiwan - TCSI | Yes |
| Mexico - INSQ | No (2,4'-diphenylmethane diisocyanate; p-toluenesulfonyl isocyanate) |
| Vietnam - NCI | Yes |
| Russia - FBEPH | No (naphtha petroleum, heavy alkylate) |
| Legend: | Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration. |

SECTION 16 Other information

| | |
|----------------------|------------|
| Revision Date | 10/03/2023 |
| Initial Date | 15/12/2016 |

SDS Version Summary

| Version | Date of Update | Sections Updated |
|---------|----------------|---|
| 6.1 | 20/08/2021 | Classification change due to full database hazard calculation/update. |
| 7.1 | 10/03/2023 | Classification change due to full database hazard calculation/update. |

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
 PC—STEL: Permissible Concentration-Short Term Exposure Limit
 IARC: International Agency for Research on Cancer
 ACGIH: American Conference of Governmental Industrial Hygienists
 STEL: Short Term Exposure Limit
 TEEL: Temporary Emergency Exposure Limit.
 IDLH: Immediately Dangerous to Life or Health Concentrations
 ES: Exposure Standard
 OSF: Odour Safety Factor
 NOAEL :No Observed Adverse Effect Level
 LOAEL: Lowest Observed Adverse Effect Level
 TLV: Threshold Limit Value
 LOD: Limit Of Detection
 OTV: Odour Threshold Value
 BCF: BioConcentration Factors
 BEI: Biological Exposure Index
 AIC: Australian Inventory of Industrial Chemicals
 DSL: Domestic Substances List
 NDSL: Non-Domestic Substances List
 IECSC: Inventory of Existing Chemical Substance in China
 EINECS: European INventory of Existing Commercial chemical Substances
 ELINCS: European List of Notified Chemical Substances
 NLP: No-Longer Polymers
 ENCS: Existing and New Chemical Substances Inventory
 KECI: Korea Existing Chemicals Inventory
 NZIoC: New Zealand Inventory of Chemicals
 PICCS: Philippine Inventory of Chemicals and Chemical Substances
 TSCA: Toxic Substances Control Act
 TCSI: Taiwan Chemical Substance Inventory
 INSQ: Inventario Nacional de Sustancias Químicas
 NCI: National Chemical Inventory
 FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.